Endocrinol Metab Clin N Am
32 (2003) 1025–1076

ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA

Cumulative Index 2003

Volume 32

March	OSTEOPOROSIS, pages 1–324
June	CONSULTATIVE ENDOCRINOLOGY, pages 325–548
September	MECHANISMS OF INFERTILITY: DOES DIAGNOSIS DICTATE THERAPY? pages 549–740
December	OBESITY, pages 741–1076

Note: Page numbers of article titles are in **boldface** type.

A

ACE inhibitors, for hypertension with obesity, 844–845

Acromegaly, fetal manifestations of, 578–579
  impaired fertility with, 578
  pituitary surgery for, during pregnancy, 342
  secondary osteoporosis from, 122
  with pituitary tumor, 356, 364

ACTH stimulation test, short, for perioperative glucocorticoid management, in preoperative assessment, 376–377
  with diabetes mellitus type 1, 432–433

Acupuncture, for surgical hypogonadotropism management, 330

Acute phase reaction, to biphosphonates, 262

Addisonian crisis, in critically ill patients, 401

Adenomas, pituitary, surgery for, clinically nonfunctioning, 341–342
    during pregnancy, 340–341

Adiponectin (APM1) gene, obesity role of, 777–778

Adipose tissue, definitional measurement of, 741–742
  excessive. See *Obesity*.
  regional distribution of, in obstructive sleep apnea, 874
    in risks with obesity, 791, 862

Adolescence, bone mass accrual during, 42–48, 55, 115, 343
  bone strength development during, 29–31
  calcium and vitamin D intake recommendations for, 342–345, 348
  phytoestrogens safety for, 249

ADRB3 (β3-adrenergic receptor) gene, obesity role of, 775–776

Adrenal androgens, bone metabolism and, 210–211

Adrenal disorders, impaired fertility with, autoimmune, 583, 619–620
    congenital hyperplasia, 581–582, 694–695
    congenital hypoplasia, 551
    Cushing's syndrome, 583–584
    in 46, XX spontaneous premature ovarian failure, 619–620, 627
    in men, 694–695
    insufficiency, 582–583, 620

Adrenal hypoplasia congenita (AHC), infertility with, 551

Adrenal insufficiency, impaired fertility with, 582–583, 620
    autoimmune, 619–620
  in critically ill patients, 400
    treatment of, 401
  perioperative management of, during pregnancy, 344–347
    evolution of, 367–368, 380–381
    HPA suppression considerations, 371–381
    hypotension pathogenesis in, 369–370
    incidence of, 369–370

0889-8529/03/$ - see front matter © 2003 Elsevier Inc. All rights reserved.
doi:10.1016/S0889-8529(03)00091-4

Adrenal *(continued)*
patient indications for, 377–379
pitfalls in study of, 370–371
preoperative assessment of adrenocortical function for, 376–377
recognition of, 368–369
specific recommendations for, 379–380

Adrenalectomy, bone metabolism after, 210

Adrenergic blockers, for hypertension with obesity, 844

Adrenocorticotropic hormone (ACTH), in adrenal disorders, 582
in critically ill patients, 371, 400–401
in human infertility, 8
obesity impact on regulation of, 901–903, 907
perioperative management of, during pregnancy, 343–344
evolution of, 367–368, 380–381
HPA suppression with, alternate day therapy and, 376
exogenous administration and, 375–376
management of, 375
time course of, 371–372
time course of recovery from, 373–374
hypotension pathogenesis in, 369–370
incidence of, 369–370
patient indications for, 377–379
pitfalls in study of, 370–371
preoperative assessment of adrenocortical function for, 376–377
recognition of adrenal insufficiency, 368–369
specific recommendations for, 379–380
with pituitary surgery, 356–360, 363
short stimulation test of, in preoperative assessment, 376–377
with diabetes mellitus type 1, 432–433

Age and aging, as bariatric surgery criteria, 440–441
as bone mass accrual factor, 42–48, 55
as osteoporosis risk factor, 1–4
based on calcium and vitamin D intake, 342–345, 348
impact on biochemical bone markers, 92
in geriatric population, 8–10, 343
as sexuality factor, 677–678
bone strength with, developmental stages of, 27–31
loss of, 25–26, 31–36
physiologic processes impacting, 25, 36–37

Age-related fertility decline, **669–688**
assisted reproductive technology for, 673, 675, 680–682
extraneous influences on, 671–672, 676–677
fecundity determinants, 669–672, 681–682
gamete aging in, 671–675, 682
genetic risks with, 673–676, 679
in vitro fertilization for, 673, 675–676, 679
conventional techniques, 680–681
experimental methods, 681
male factors of, 671–674, 682
management of, 680–682
neuroendocrine axis and, 678
pregnancy and, 675–676
prognosticators of, 678–680
research review, 669–670, 682
sexuality and, 677–678

AIRE gene, in human infertility, 563–564

Airway occlusion, upper, in obstructive sleep apnea, 872–873

Alcohol intake, as cause of secondary hypogonadism, 599–600
as male infertility factor, 700
as osteoporosis risk factor, 8, 125–126
as peak bone mass factor, 56–57

Aldosterone, pregnancy and, 347–348

Alendronate, for osteoporosis, glucocorticoid-induced, 145
guidelines for, 255–258
postmenopausal, calcitonin therapy and, 281
with parathyroid hormone, 297

Alkaline phosphatase (ALP), as biochemical bone marker, 84–85, 236–238

Allele-sharing studies, of osteoporosis genes, 67–68
quantitative trait loci in, 69–71

Alpha-estrogen receptors, deficiency in men, bone metabolism and, 196
genetic knockout models of, 200–203
gene for, osteoporosis susceptibility based on, 74–75
phytoestrogen mechanism of action through, 235–236

α-Blockers, for pheochromocytoma, during pregnancy, 350–351

Amenorrhea, in 46, XX spontaneous premature ovarian failure, 615, 621, 624, 626
in athletes, secondary osteoporosis from, 118
primary versus secondary, 596
with adrenal disorders, 582–583
with diabetes, 580
with hyperthyroidism, 574–575
with hypogonadotropic hypogonadism, 593
hypothalamic, 595–597
postpill, 599
psychogenic, 599
treatment of, 606–607
with polycystic ovary syndrome, 639–641

American College of Sports Medicine (ACSM), on exercise for obesity, 970–976

AMH gene, in human infertility, 564–565

AMHR2 gene, in human infertility, 564–565

Aminoglutethamide, as teratogenic, 584

Anabolic androgenic steroids, hypogonadotropic hypogonadism from, 601, 696–697

Anabolic therapy(ies), in osteoporosis, **285–307**
biphosphonates with, 264
conceptual basis for, 285, 300
fluoride as, 286–287
glucocorticoid-induced, 147
growth hormone as, 287–288
insulin-like growth factor as, 287–288
parathyroid hormone as, as combination with alendronate, 297
as combination with estrogen, 295–296
as monotherapy post menopause, 292
concerns about, 299–300
continuous versus intermittent, 291–292
in glucocorticoid-induced osteoporosis, 297
in men, 292–295
withdrawal of, 298

Analgesia, calcitonin as, 279–280

Analytical variability, of bone marker measurements, 88–91

Androgen(s), bone metabolism role of, **195–218**
adrenal, 210–211
clinical summary of, 195–196, 213
gender non-specificity of, 212–213
in women, 208–212
in male factor infertility, 695–696

Androgen insensitivity syndrome (AIS), genetics of, 565–566, 695–696
secondary osteoporosis from, 120, 208–209

Androgen replacement therapy, for premature ovarian failure, 630

Anemia, following bariatric surgery, 454–455

Aneuploidy(ies), in age-related infertility, 673–674, 679–680

Animal studies, of osteoporosis genes, 68–69

Anorexia nervosa, secondary hypogonadism with, 598–599
secondary osteoporosis from, 117–119

Anovulation, in polycystic ovary syndrome, **639–651**
cause of, 641–642
clinical characteristics of, 639
diagnosis of, 640–641
insulin and, 641–642
management of, 642–648
prevalence of, 639–640

Anti-resorptive agents, for osteoporosis, 253–271. See also *specific drug*.
combining with other treatments, 264
dosing of, 260
duration of therapy, 265
fracture risk reduction with, 255–257
glucocorticoid-induced, 144–146, 149
in special clinical circumstances, 262–264
mechanism of actions, 253–254
monitoring response to, 265
rationale for, 127, 253–254, 265–266, 290–291, 347
side effects of, 260–261
skeletal effects of, 253–255
specific drugs, 255–260
surrogate end-point markers for, 170–176
tolerability of, 260–261

Anticonvulsants, secondary osteoporosis from, 130–131

Antidiuretic hormone (ADH), hypothyroidism impact on, 511

Antiepileptic drugs, in obesity therapy, 1018–1019

Antihypertensive drugs, for hypertension with obesity, 844–846

Antiobesity drugs, for hypertension with obesity, 845–846

Antiprogestins, as teratogenic, 584

Antithyroid antibodies (ATAs), as infertility factor, 576–577

Antithyroid drugs (ATD), for thyrotoxicosis, 524–528
  surgical risks with, 529–531

APM1 (adiponectin) gene, obesity role of, 777–778

Apolipoprotein E, osteoporosis susceptibility based on, 76

Appetite suppressants, in obesity therapy, 1020–1021

AR gene, in human infertility, 565–566

Arginine vasopressin (AVP), cirrhosis impact on, 471–472
  congestive heart failure and, 471
  following pituitary surgery, 361, 364–365
  glucocorticoid deficiency role of, 470
  hyponatremia role in psychiatric patients, 470
  hypothyroidism and, 470
  SIADH role of, 467–469
  total body water homeostasis role, 461–462
    during pregnancy, 344

Aromatase deficiency, in men, bone metabolism and, 196–200
    genetic knockout models of, 200–203

Aromatase inhibitor, for male factor infertility

Ash density, as bone load capacity factor, 27–29

Assisted reproductive technology (ART). See also *specific technique*.
  for aging-related infertility, 673, 675, 680–682
  for endometriosis-associated infertility, 661
  for male factor infertility, 691–693, 699

Association studies, of osteoporosis genes, candidate, 67–68, 72–77

Asthenospermia, WHO criteria for, 558

Athletes, anabolic steroids used by, 601, 696–697
  female, menstrual irregularities due to, 597–598, 601
    with amenorrhea, secondary osteoporosis in, 118

Atkins Diet, for obesity, 954–955

Atresia, of ovarian follicles, 614, 620, 671

Autoimmune adrenal insufficiency, impaired fertility with, 583
  in 46, XX spontaneous premature ovarian failure, 619–620

Autoimmune lymphocytic oophoritis, in 46, XX spontaneous premature ovarian failure, 617–620, 627, 631

Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), genetics of, 563–564

Autoimmune thyroid disease (ATD), in pregnant women, 576–577

Autosomal genes, in hypogonadal infertility, 551–552
    chromosomal abnormalities, 555, 561–565
  translocations of X-chromosome, 557–558, 698

Azoospermia, genetics of, 549–550, 554, 559–561, 697
  in male infertility, 691, 699
  outflow tract disorders, 565–566
  WHO criteria for, 558, 691

Azoospermia factor (AZF), in Y chromosome abnormalities, 559–561, 698

B

Balanced Deficit Diet, for obesity, 944, 953–954
    maintenance of, 953–958

Bardet-Biedl syndrome, secondary hypogonadism with, 602–603

Bariatric surgery, for morbid obesity, **439–459**
  age criteria for, 440–441
  comorbidities with, improvements in, 452–455

management preoperatively, 441–442
complications of, 447–455
contraindications for, 441
eating behavior and, 450–451
gallbladder disease and, 451–452
increasing need for, 439–440, 455
laparoscopic, 445–446
long-term management of, 448–452
patient education expectations for, 442, 450
patient selection for, 440–441
postoperative management of, 447–448
preoperative management of, 441–443
prevalence of, 439–440, 455–456
procedures for, 444–446
comparison of, 446–447
concerns with, 447–448
screening evaluation for, 442–443
special facilities for, 443–444
support staff for, 443–444
weight loss with, based on procedure, 444, 446–447
benefits of, 452
patient expectations for, 442, 450
with type 2 diabetes, 815–816

Basal energy expenditure (BEE), in obesity assessment, 942–943

Basic multicellular unit (BMU), in aging bone remodeling, 25, 31–32, 36–37

Bazedoxifene, for postmenopausal osteoporosis, 230

Behavior, as peak bone mass factor, 52–57

Behavioral assessment, for obesity, 940

Behavioral modification treatment, of obesity, **983–1005**
characteristics of, 985–986
cognitive restructuring with, 987–988
components of, 987–988
diet focus, high-protein, low-carbohydrate, 991
low-fat, low-energy-dense, 998–999
meal replacements, 990
portion-controlled servings, 990–991
very-low-calorie, 990
with type 2 diabetes, 809–813
evidence for, 983
exercise and, 979–980, 987
high levels of, 996–998
with type 2 diabetes, 812
hypertension and, 844
in toxic environment, 999–1000
long-term results of, 991–995
limitations of, 993–994
telephone and mail contact, 994
with on-site treatment, 992
national control registry for, 995–996
principles of, 983–985
research strategies for, 999–1000
self-monitoring of, 986
short-term results of, 989–991
stimulus control in, 986–987
structure of, 988–989
translational research for, 999
with exercise, 979–980, 987
high levels of, 996–998
with type 2 diabetes, 812–813

Bending strength stress, as bone load capacity factor, 26–28

Beta-estrogen receptors, deficiency in men, genetic knockout models of, 201–203
phytoestrogen mechanism of action through, 235–236

β-Blockers, for thyrotoxicosis perioperative management, 522–524, 526–527, 530–531
emergent preparation, 532–533
pregnancy cautions with, 350

β_3-Adrenergic receptor (ADRB3) gene, obesity role of, 775–776

β_3Agonists, in obesity therapy, 1019–1020

Bias, selection, in clinical research trials, 715, 721

Biliary cirrhosis, primary, secondary osteoporosis from, 125

Biliopancreatic diversion (BPD), as bariatric surgery, 444–445, 447
nutritional considerations with, 451, 454–455

Biochemical bone markers, aging effects on, 92
basic biochemistry of, formation, 84–85, 87
resorption, 86–88
in osteoporosis, 92–105
bone loss prediction with, 94–97
current trials on, 92–93
fracture risk prediction with, 97–99, 104
of bone remodeling, 93–94

Biochemical *(continued)*
therapy and, 99–105
measurement variability with, 88–91
menopause effects on, 92
nasal spray calcitonin impact on, 277–278
of formation versus resorption, 84–88
phytoestrogens impact on, 241–245
clinical trials on, 246–249
caveats in interpretations of, 241
synthetic agents, 249–250

Biochemical markers, of endometriosis-associated infertility, 656
of ovarian reserve, 678

Biochemical mediators, of hypertension with obesity, 828–835

Biomechanical basis, of bone strength, **25–38**
developmental growth stages of, 27–28, 31–36
fragility fractures and, 25–26, 36–37
in aging bones, 25, 31–36
in periosteal and endosteal surfaces, 30–31
in young bones, 27–32
key concepts in, 25–26, 36–37
"right stuff" for functional, 26–29, 36

Biphosphonates, for osteoporosis, **253–271**. See also *specific drug*.
clinical trials of, 175–176
combining with other treatments, 264
dosing of, 260
duration of therapy, 265
fracture risk reduction with, 255–257
glucocorticoid-induced, 144–146, 149
in special clinical circumstances, 262–264
mechanism of actions, 253–254
monitoring response to, 175, 265
preventative with surgical hypogonadotropism, 332
rationale for, 127, 253–254, 265–266, 290–291, 347
side effects of, 260–261
skeletal effects of, 253–255
specific drugs, 255–260
surrogate end-point markers for, 170–176
tolerability of, 260–261

Bleeding, following thyroidectomy, for thyroid carcinoma, 487–488

Blepharophimosis/ptosis/epicanthus inversus syndrome (BPES), 624–625

Blood urea nitrogen (BUN), hypothyroidism impact on, 511–512

Body fat, definitional measurement of, 741–742
excessive. See *Obesity*.
mobilization of, in obesity therapy, 1021
regional distribution of, in obstructive sleep apnea, 874
in risks with obesity, 791, 862

Body mass index (BMI), calculation of, 742
in bariatric surgery criteria, 440, 446–447
with obesity, 742–744
assessment guidelines for, 922–925, 941
determinants of, 751–753, 1008
distribution trends for adults and children, 750–751
genome scans correlation with, 765–769
hypertension and, 824
in obstructive sleep apnea, 872, 874
risks associated with, 787–799

Body weight, excessive. See *Obesity*.

Bone densitometry, clinical utility and application of, **159–180**
for disease progression and therapy monitoring, 170–176
for fracture risk prediction, 166–170
for osteoporosis diagnosis by WHO criteria, 159–166
standard deviation scores in, 159–160, 162–165, 169
T score variances in, 160–165

Bone formation, biochemical markers of, basics of, 85, 87
bone remodeling versus, 84–86
biphosphonates impact on, 261–262
fragility with failure of, 25–26, 31–36
with osteoporosis, 16, 18–20

Bone fragility, biomechanical basis of, 25–26
in aging bones, 31–36

Bone loss, with osteoporosis, biochemical markers of, 94–97

Bone markers. See *Biochemical bone markers*.

Bone marrow, disorders of, secondary osteoporosis from, 129
transplantation of, secondary osteoporosis from, 127

Bone mass, accrual factors of, 41–46
determinants of, 46–57
low, with osteoporosis, 16
peak. See *Peak bone mass*.
regulation of, osteoporosis genes and, 69–71

Bone measurement techniques, for mineral content, 39–41
for mineral density. See *Bone densitometry*.
for osteoporosis, 2–3, 141
for peak bone mass, 41, 43, 45–48

Bone metabolism, sex steroids role in, 195–196, 213
gender non-specificity of, 212–213
in men, 196–208
in women, 208–212

Bone mineral content (BMC), as bone load capacity factor, 27–29
in aging bones, 25–26
measurement techniques for, 39–41

Bone mineral density (BMD), anabolic therapy impact on, 286–300
conceptual basis for, 285, 300
fluoride, 286–287
growth hormone, 287–288
insulin-like growth factor, 287–288
parathyroid hormone, as
combination with alendronate, 297
as combination with estrogen, 295–296
as monotherapy post menopause, 292
concerns about, 299–300
continuous versus intermittent, 291–292
in glucocorticoid-induced osteoporosis, 297
in men, 292–295
withdrawal of, 298
as bone load capacity factor, 27–30
drugs for enhancing, 37
in aging bones, 33–36
bone mineral content versus, 40
calcitonin impact on, injectable, 273–274
nasal spray, 274–275
clinical utility and application of, **159–180**
for disease progression and therapy monitoring, 170–176
for fracture risk prediction, 166–170
for osteoporosis diagnosis by WHO criteria, 159–166
genetic determinants of, 65–77
measurement of. See *Bone densitometry*.
phytoestrogens impact on, 241–245
clinical trials on, 246–249
caveats in interpretations of, 241
synthetic agents, 249–250
selective estrogen receptors modulators impact on, 221–223
sex steroids role in, 195–213
gender non-specificity of, 208–213
in men, 196–208
in women, 208–212

Bone morphogenetic proteins (BMPs), in bone formation regulation, 19–20

Bone remodeling, biochemical markers of, **83–113**
aging effects on, 92
basics of, 86–88
bone formation versus, 84–86
in osteoporosis, 92–105
measurement variability with, 88–91
menopause effects on, 92
bone formation impairment during, 20
in aging bones, 25–26
failure of, 31–36
reduction of rate of, 37
with osteoporosis, 16–18, 342
anabolic therapy impact on, 285, 300
biochemical markers of, 92–105
biphosphonates impact on, 253–255, 257
glucocorticoid-induced, 139–140

Bone remodeling units (BRU), coupling defects of, 20–21

Bone replacement. See *Bone turnover*.

Bone resorption. See *Bone remodeling*.

Bone sialoprotein (BSP), as biochemical bone marker, 86, 88

Bone-specific alkaline phosphatase (BSAP), anabolic therapy impact on, 289–290
as biochemical bone marker, 84–85, 211

Bone strength, structural and biomechanical basis of, **25–38**

Bone *(continued)*
developmental growth stages of, 27–28, 31–36
in aging bones, 25, 31–36
in periosteal and endosteal surfaces, 30–31
in young bones, 27–32
key concepts in, 25–26, 36–37
"right stuff" for functional, 26–29, 36

Bone turnover (BMC), anti-resorptive therapy surrogate markers for, 170–176
during aging, 25–26
in osteoporosis, anabolic therapy impact on, 286–300
biochemical markers of, 92–105
pre-treatment role of, 100–101
predictions based on, 92–100
therapeutic monitoring role of, 101–105
monogenic bone disease impact on, 69–70
nasal spray calcitonin impact on, 277–278
selective estrogen receptors modulators impact on, 102, 220–221

Botanicals, for surgical hypogonadotropism management, 328

Breaking strength/stress, bone capacity for, 26–28

Breast(s), selective estrogen receptors modulators impact on, 228–229

Breast cancer treatments, as cause of secondary hypogonadism, 601–602

Bromocriptine, for acromegaly during pregnancy, 579
for prolactinomas, during pregnancy, 340–341

Bulk, as bone load capacity factor, 26

C

CA-125 antibodies, in endometriosis-associated infertility, 656

Caffeine, in obesity therapy, 1019–1020

Calcitonin, **273–284**
administration of, 280
analgesic effects of, 279–280
for osteoporosis, early menopausal, 275–277
glucocorticoid-induced, 143–144, 278–279
in combination therapy, 281
postmenopausal, 273–275, 282
for osteoporosis prevention, with surgical hypogonadotropism, 332
in bone resorption regulation, 17–18
injectable, for postmenopausal osteoporosis, 273–274
nasal spray, effect on bone turnover markers, 277–278
effect on fracture reduction, 275–278
effect on menopausal osteoporosis, 274–277
for men with idiopathic osteoporosis, 278
physiology of, 273
resistance to, 280–281
side effects of, 280
therapeutic indications for, 273

Calcitriol, role in vitamin D absorption, 340–342

Calcium, absorption of, bariatric surgery and, 455
deficiency of, bone remodeling and, 92
secondary osteoporosis from, 117–119, 122–123
dietary, as peak bone mass factor, 53–56
intake recommendations for, 344–345
sources of, 348
for osteoporosis, **339–352**
glucocorticoid-induced, 142–143
natural versus supplemental sources of, 348
physiology of, 339–340
preventative with surgical hypogonadotropism, 332
preventive guidelines for, 342–345
supportive guidelines for, 345–348
retention of during adolescence, 343–344

Calcium blockers, for hypertension with obesity, 844

Calcium supplements, 92, 348–349

Calorie expenditure, with physical activities, 959

Cancer, as obesity risk, 788–789, 800

Cancer treatments, as age-related infertility factor, 677

as cause of secondary hypogonadism, 601–602
as male infertility factor, 700–701

Candidate genes, as peak bone mass factor, 49–50
osteoporosis susceptibility based on, association studies of, 72–77
polymorphisms of other, 77

Cannabinoid receptor (CB1) antagonists, in obesity therapy, 1018

Carbohydrate intake, in obesity treatment programs, 954–956

Cardiac activity, fetal ultrasonography of, in older pregnant women, 675–676

Cardiac adaptation, with hypertension and obesity, 840–842

Cardiac output, hypothyroidism impact on, 505–506, 516

Cardiometabolic syndrome. See *Metabolic syndrome*.

Cardiovascular disease, selective estrogen receptors modulators impact on, 226–227

Cardiovascular system, bariatric surgery impact on, 441, 443
hypothyroidism impact on, 505–509, 516
obesity impact on, hypertension and, 839–841
obstructive sleep apnea and, 876–879
treatment strategies for, 931–932, 956–958
thyrotoxicosis impact on, 529–530

Catecholamines, obesity impact on regulation of, 904–906

Cbfa-1/Runx-2, in bone formation regulation, 19

Celiac disease, secondary osteoporosis from, 123

Central nervous system (CNS), hyponatremia role of, 470, 474–477
lesions of, as male infertility factor, 702
role in obstructive sleep apnea, 872–874

Central obesity, 825, 879, 886

Cerebrospinal fluid (CSF), leakage of, following pituitary surgery, 362

Cerebrovascular disease, obstructive sleep apnea association with, 878–879

CFTR gene, in human infertility, 566, 702

Change strategies, in behavioral treatment of obesity, 986

Charcoal plasmaperfusion, for thyrotoxicosis perioperative management, 528

Chemotherapeutic drugs, as age-related infertility factor, 677
as cause of secondary hypogonadism, 602
as male infertility factor, 700–701

Children, osteoporosis risks in. See also *Adolescence*.
biphosphonates for, 263

Chocolate cyst, infertility associated with, 655

Cholecystographic agents, oral, for thyrotoxicosis perioperative management, 524, 527
emergent preparation, 532–533

Choledocholithiasis, bariatric surgery and, 450–452

Cholelithiasis, bariatric surgery and, 441, 443, 450–452

Cholesterol level. See *Lipoproteins*.

Chromosome 1, obesity role of, 765–769

Chromosome 2, obesity role of, 765–769

Chromosome 3, obesity role of, 765–770

Chromosome 5, obesity role of, 766–770

Chromosome 6, obesity role of, 766–771

Chromosome 7, obesity role of, 766–769, 771

Chromosome 8, obesity role of, 766–769, 771–772

Chromosome 9, obesity role of, 766–769, 772

Chromosome 10, obesity role of, 766–769, 772–773

Chromosome 11, obesity role of, 766–769, 773

Chromosome 12, obesity role of, 766–769, 773

Chromosome 13, obesity role of, 766–769, 773

Chromosome 16, obesity role of, 766–769, 774

Chromosome 17, obesity role of, 766–769, 774

Chromosome 20, obesity role of, 766–769, 774

Chromosome mutations. See also *specific chromosome*.
as obesity factor, 765–774
in human infertility, 555–565
autosomal, 555, 561–565
in men, 697–699
of X chromosome, 554–559, 698
of Y chromosome, 554–555, 559–561, 698–699
obstructive sleep apnea relationship with, 882–883

Chromosome X, obesity role of, 766–769, 775

Chromosomes, as peak bone mass factor, 49
osteoporosis susceptibility based on, 69–77

Ciliary neurotrophic factor, in obesity therapy, 1017–1018

Cirrhosis, hypo-osmolality versus, 471–472

Civil trials, clinical trials versus, 716–717, 721–722

Classical conditioning, in behavioral treatment of obesity, 984–985

Clinical trials, of infertility intervention, epidemiologic designs of, 712–713
jury trials versus, 716–717, 721–722
noninformative design for, 710–712
randomized, 715, 719
research context, 713–715

Clomiphene citrate, for age-related infertility, 682
for endometriosis-associated infertility, 659
for polycystic ovary syndrome, 643

Clomiphene citrate challenge test (CCCT), for ovarian reserve assessment, 679–680

Clonidine, transdermal, for surgical hypogonadotropism management, 327

Clotting factors, hypothyroidism impact on, 512–514

Coagulation systems, hypothyroidism impact on, 512–514

Coagulopathy. See *Hypercoagulation*.

Cochran Collaboration listing, of infertility clinical trials, 719

Coefficient of variation percentage (CV%), in bone marker measurements, 173–174

Cognitive therapy, in behavioral treatment of obesity, 984, 987–988

Coitus, frequency of, aging and, 677–678
lubricants during, as infertility factor, 669–670

Collagen propeptides, as biochemical bone markers, of formation, 84–85, 87
of resorption, 86–88, 90–95, 99–104

Collagen type I alpha 1 gene, osteoporosis susceptibility based on, 71, 73–74

Combination therapy, for osteoporosis, calcitonin, 281
parathyroid hormone, 295–297

Comorbidities, of diabetes mellitus type 1, perioperative management of, 413
with morbid obesity, bariatric surgery improvements for, 452–455
preoperative management of, 441–442

Completion thyroidectomy, for thyroid carcinoma, 498–500

Computed tomography (CT), for osteoporosis. See *Quantitative computed tomography (QCT)*.

Conception. See *Pregnancy*.

Congenital adrenal hyperplasia (CAH), impaired fertility with, 581–582, 694–695

Congenital bilateral absence of the vas deferens (CBAVD), as male infertility factor, 701–702
genetics of, 565–566, 702

Congenital central hypogonadism, 595, 603–605

Congestive heart failure (CHF), hypo-osmolality versus, 471
hypothyroidism impact on, 507, 509

Connectivity, in bones, loss with aging, 33–34, 36

Consequences, in behavioral treatment of obesity, 984

Continuous variables, in infertility intervention trials, 720

Coronary artery bypass surgery (CABG), diabetes mellitus type 1 management during, 418–419, 428–429
thyroid hormone management during, 508

Coronary heart disease (CHD), as obesity risk, 788, 791, 793–794, 798–800
treatment strategies for, 931–932
obstructive sleep apnea association with, 878–879

Cortical bone, aging remodeling of, 28–33, 35–36
gender differences in, 167–168

Corticosteroids, for thyrotoxicosis perioperative management, emergent preparation, 532–533

Corticotropin-cortisol, obesity impact on regulation of, 901–903

Corticotropin-releasing hormone (CRH), diabetes mellitus and, 580
glucocorticoid therapy impact on, 372
in adrenal disorders, 582
in critically ill patients, 400
in obesity regulation, 901–903, 907

Cortisol. See also *Glucocorticoid replacement therapy*.
as hypertension factor with obesity, 831–832
in critically ill patients, 371, 400–401
perioperative management of, 371, 378
during pregnancy, 344–347
with pituitary tumor, 356–361, 363

Cortisone therapy, perioperative management of. See *Adrenocorticotropic hormone (ACTH)*.

Costs, health care, of obesity, 787–789
of weight management programs, 960–961

Coupling defects, in osteoporosis pathogenesis, 20–21

CPAP, nasal, for obstructive sleep apnea, 884–886

Cranial tumors, as cause of secondary hypogonadism, 603
irradiation impact, 602

Critical illness, endocrine evaluation with, **385–410**
as adverse outcome predictors, 401–403
cortisol levels in, 371, 400–401
lactotropic axis of, 397–398
luteinizing hormone-testosterone axis of, 398–400
pituitary-adrenal axis of, 400–401
somatotropic axis of, 386–393
summary definitions for, 385–386, 404
thyrotropic axis of, 393–397

Cross section area (CSA), in aging bone remodeling, 25, 30, 32, 36

Crosslinked telopeptides, as biochemical bone marker, 86, 88

Cryptorchidism, genetics of, 564–565
in male factor infertility, 699

CTX level, as variable, in bone marker measurements, 90–91
with calcitonin therapy, 276–278, 280

Cushing's syndrome, associated with obesity, 903, 907, 928
bariatric surgery and, 443
fetal outcomes of, 345–347
from steroids, for impaired fertility, 627
impaired fertility with, 583–584
in critically ill patients, 400–401
maternal outcomes with pregnancy, 345–347
perioperative management of, during pregnancy, 344–347
with glucocorticoid therapy, 367, 373, 378
with pituitary tumor, 356–360, 362–363

CYP17 gene, in human infertility, 562–563

CYP17 gene mutations, in 46, XX spontaneous premature ovarian failure, 625

CYP19 gene mutations, in 46, XX spontaneous premature ovarian failure, 626

Cystic fibrosis (CF), as male infertility factor, 702

Cytokines, in bone resorption regulation, 17
with hypertension and obesity, 842

D

Daidzein, as phytoestrogen source, 234
bone mineral density and, clinical trials on, 247–248
mechanism of action, 235–236, 239

DASH Diet, for obesity, 955, 957

Dax1 gene, in male factor infertility, 694

Death, as obesity risk, 793–794, 917
following bariatric surgery, 447–448

Deep venous thromboses (DVT), following bariatric surgery, 448

Dehydroepiandrosterone sulfate (DHEAS), in critically ill patients, 400

11 β-Dehydrogenase deficiency, associated with obesity, 910

Demeclocycline, for hyponatremia, 478

Denys-Drash syndrome, genetics of, 555, 564

Deoxypyridinoline (DPD), as biochemical bone marker, 86–88, 91–92, 95, 97, 101

Dependent variables, in infertility intervention trials, 720

Depression, bariatric surgery and, 448–449

170–20-Desmolase deficiency, impaired fertility with, 625, 695

Desmopressin replacement therapy, following pituitary surgery, 361, 364–365

Developmental growth stages, of bone strength, 27–28, 31–36

Dextrose infusions, for perioperative management, of diabetes mellitus type 1, 418–424
GIK protocol for, 416–417, 420–421, 424

DHEA therapy, for women with osteoporosis, 211

DHH gene, in human infertility, 565

Diabetes insipidus (DI), pituitary surgery and, 356, 361
during pregnancy, 343–344

Diabetes mellitus. See also *specific type*, impaired fertility with, 579–581, 703
secondary osteoporosis from, 121
with polycystic ovary syndrome, 642

Diabetes mellitus type 1, perioperative management of, **411–437**
comorbidity effects on, 413
detrimental effects of hyperglycemia on, 414–416
discharge planning in, 425–427
GIK infusion for, 416–417, 420–421, 424
glucose dosing algorithms, 418–424
glucose monitoring for, 421
in non-cardiac versus cardiac patients, 420, 424
incidence of, 411
insulin dosing algorithms, 418–424
pathophysiology of, 412–413
postoperative care for, 425–427
preoperative evaluation for, 413
preoperative preparation for in-patient status, 416–417, 419
scope of, 411–412, 433
special scenarios with, 428–433
with cardiopulmonary bypass surgery, 418–419, 428–429
with enteral or parenteral nutrition, 429–432
with glucocorticoid management, 432–433
with hyperglycemia management, 432–433
with urgent and emergent surgery, 428

Diabetes mellitus type 2, obesity and, **805–822**
assessment for, 938–939
diagnosis of, 928
impact on, 806–807
prevention of, 816–818, 983, 999
risk association between, 788, 793–796, 805–806
treatment of, 809–816, 932
bariatric surgery, 815–816
behavioral therapy, 812–813
diet, 809–812
exercise, 812
pharmacotherapy, 813–815
weight loss benefits for, 807–809

Diabetes Prevention Program, impact on obesity, 816–818, 983, 999
assessment guidelines, 932, 938–939

DIAPH2 gene, in human infertility, 558

Dichotomous variables, in infertility intervention trials, 720

Diet(s). See *Nutrition therapy:specific diet*.

Dietary calcium, as peak bone mass factor, 53–56

Digestive system, hypothyroidism impact on, 516–517

Dihydrotestosterone (DHT), bone metabolism role of, in men, 196, 204–208
in women, 209, 212
in male factor infertility, 695–696

Dilation(s), as male infertility factor, ejaculatory duct and seminal vesicles, 701–702
spermatic veins, 691–693

Diminished ovarian reserve (DOR), 678

Diuretics, for hypertension with obesity, 845

DNA mutations, in age-related infertility, 674, 681

DNAH5 gene, in human infertility, 565

Dopamine agonists, for prolactinomas, during pregnancy, 340–341

Droloxifene, for postmenopausal osteoporosis, 229

Drug therapy(ies), as cause of secondary hypogonadism, opioids, 600–601
prescription, 601
as male infertility factor, 700–701, 703
cautions with pregnancy, 584
for bone remodeling reduction, 37
for hyponatremia, 478–479
for obesity, **1007–1026**
Food and Drug Administration approved, 959–960, 1009–1016
meta-analysis of, 1007–1009, 1022
potential future, 1016–1021
for obesity-related diseases, history taking with, 922, 939
hypertension as, 844–846
type 2 diabetes as, 813–815, 932
for surgical hypogonadotropism, herbal and botanical, 328
traditional non-hormone, 327–328, 332–333
for thyrotoxicosis, 524–528
surgical risks with, 529–531
secondary osteoporosis from, 117, 130–131

Drug use, illicit, as male infertility factor, 700

Dual energy x-ray absorptiometry (DXA), as measurement technique for osteoporosis, 40–41
age-related, 2
gender-related, 196
glucocorticoid-induced, 140
WHO criteria for, 160–166
with anti-resorptive agent surrogate markers, 173–175

Dumping syndrome, with bariatric surgery, 447, 453

Dysgenesis, mixed gonadal, in male factor infertility, 698

Dyslipidemia, obesity and, **857–869**
bariatric surgery impact on, 452
lipoproteins and body weight relationship, 857–863
pathophysiology of, 863–867
risks of, 791, 793, 799

E

E-mail, in behavioral treatment of obesity, 994–995

Early menopause, osteoporosis risks with, calcitonin therapy for, 275–277

Eating behavior, bariatric surgery and, 450–451
modification for obesity. See *Behavioral modification treatment.*

Eating disorders, secondary osteoporosis from, 117–119

Edema, tracheal, following thyroidectomy, 487

Ehlers-Danlos syndrome, secondary osteoporosis from, 116, 128

Ejaculation disorders, in male factor infertility, 702–703

Ejaculatory duct obstruction (EJDO), as male infertility factor, 701

Elasticity, as bone load capacity factor, 26–27

Elderly patients. See *Geriatric population.*

Electrocardiogram, hypothyroidism impact on, 507, 509

Electrolyte balance, hypothyroidism impact on, 507, 509, 511–512

Embryo development, preimplantation, diabetes mellitus impact on, 580–581

Emergent surgery, diabetes mellitus type 1 management during, 428
thyrotoxicosis management during, 531–533

Enbryo-uterine cross-talk, as fecundity factor, 670–671

Endocrine dysfunction, impaired infertility caused by, **573–592**
adrenal disorders, 581–584
diabetes, 579–581
growth hormone and acromegaly, 578–579

Endocrine *(continued)*
in men, 693–697
thyroid disorders, 573–577
male infertility with, 693–697
androgen disorders, 695–696
follicle-stimulating hormone disorders, 695
genetic, 693–695
gonadotropin-releasing hormone disorders, 693–695
hormone findings in, 693–694
luteinizing hormone disorders, 695
nongenetic, 696–697
obesity and, **897–916**
as risk factor, 788, 800–801
diseases associated with, 907–910
Cushing's syndrome, 903, 907
11 β-dehydrogenase deficiency, 910
genetic sydromes, 909
growth hormone deficiency, 907
hypogonadism, 905, 908
hypothyroidism, 907
insulinoma, 908
monogenic mutations, 908–909
polycystic ovarian syndrome, 908
traumatic hypothalamic obesity, 908
fat cell as organ of, 909
regulation mechanisms, 897–907
of catecholamines, 904–906
of corticotropin-cortisol, 901–903
of growth hormone, 899–901
of parathyroid hormone, 906–907
of prolactin, 898–899
of renin-aldosterone, 906
of sex hormones in men, 903–905, 908
of thyroid hormones, 897–898
osteoporosis from, 16
as secondary, 116, 120–122

Endocrine evaluation, with critical illness, **385–410**
as adverse outcome predictors, 401–403
cortisol levels in, 371, 400–401
lactotropic axis of, 397–398
luteinizing hormone-testosterone axis of, 398–400
pituitary-adrenal axis of, 400–401
somatotropic axis of, 386–393
summary definitions for, 385–386, 404
thyrotropic axis of, 393–397
with surgery. See *Surgery*.

Endocrine stress response, perioperative management of. See *Perioperative management*.
with critical illness, 371, 385–404
with surgery. See also *Surgery*.
pituitary, 357–359
type 1 diabetes mellitus and, 411–433

Endometrial implantation, as fecundity factor, 670–672
embryo development prior to, diabetes mellitus impact on, 580–581

Endometriomas, ovarian, infertility associated with, 655, 659–660
surgical extirpation of, 660, 662

Endometriosis-associated infertility, evidence-based evaluation of, **653–667**
assisted reproductive technology for, 661
associated mechanisms of, 657–660
clinical appearance of, 655
definition of, 653
diagnostic modalities of, 655–656
epidemiology of, 653–654
medical treatment of, 661
research summary, 662
surgical treatment of, 660, 662
symptoms and signs of, 654
treatment impact on fertility rates, 660–662

Endometriosis Fertility Index (EFI), 657

Endometriotic implants, for endometriosis-associated infertility, 661

Endosteal bone, development of surface strength of, 30–31, 36

Energy balance, with obesity, adjust to prevent weight regain, 959–960
as compromised, 938
assessments of, 941–943
maintain balanced deficit for weight loss, 954–958

Energy expenditure enhancers, in obesity therapy, 1021

Enteral nutrition, diabetes mellitus type 1 management with, 429–432

Environment, as peak bone mass factor, 52–57

Enzymes, as biochemical markers, of bone remodeling, 83–88

Ephedra, in obesity therapy, 1019–1020

Epidemiologic research design, for infertility intervention efficacy, 712–713

Epidemiology, of endometriosis-associated infertility, 653–654
of glucocorticoid-induced osteoporosis, 135–139
of obesity, **741–760**
definitions with, for adolescents, 743–744
for adults, 742–743
for children, 743–744
for measurement of, 741–742
environmental determinants, 751–753
host determinants, 751–753
prevalence of, 744–751
adolescent trends, 745, 748–751
adult trends, 745–747
body mass distribution trends, 750–751
children trends, 745, 748–750
preventive efforts based on, 754–755
public health impact issues, 755–756
risk factors of, 753–754
with hypertension, 823–824
of obstructive sleep apnea, 871–872, 887
of osteoporotic fractures, 1–10

Epididymal sperm aspiration, microsurgical (MESA), for sperm retrieval, 701

Epididymis, obstruction of, as male infertility factor, 701–702

Epinephrine, obesity impact on regulation of, 905–906

Error(s), in clinical research trials, 715–718

Estradiol, bone metabolism role of, in men, 196, 204–208
in 46, XX spontaneous premature ovarian failure, 616–617, 624–625, 630
in male factor infertility, 690, 693, 697
phytoestrogen similarity to, 235

Estrogen(s), bone metabolism role of, **195–218**
clinical summary of, 195–196, 213
gender non-specificity of, 212–213
in men, 196–208
alpha-estrogen receptor deficiency, 196
animal "knockouts" of genes, 200–203
aromatase deficiency, 196–200
studies in adults, 204–208
in surgically hypogonadal patients, osteoporosis prevention and treatment, 331–333
overview of, 325–326
urogenital symptom treatment, 333–334
vasomotor symptom treatment, 326–331
pituitary surgery impact on, 359, 361, 364–365

Estrogen cream, for surgical hypogonadotropism management, 333–334

Estrogen deficiency, in 46, XX spontaneous premature ovarian failure, 626, 628
replacement strategies for, 628–631
osteoporosis from, 16, 21, 33
in men, 199–200
premenopausal secondary, 115–116, 118–120

Estrogen receptors, alpha, deficiency in men, bone metabolism and, 196
genetic knockout models of, 200–203
gene for, osteoporosis susceptibility based on, 74–75
phytoestrogen mechanism of action through, 235–236
beta, deficiency in men, genetic knockout models of, 201–203
phytoestrogen mechanism of action through, 235–236

Estrogen replacement therapy (ERT), for men, with aromatase deficiency, 199, 201
for postmenopausal osteoporosis, 137, 281, 291
biphosphonate therapy with, 264
bone markers of, 100–101
calcium and vitamin D intake with, 340, 346–347

Estrogen *(continued)*
glucocorticoid-induced, 144
limitations of, 219, 340
phytoestrogens impact on, 240–242
with parathyroid hormone, 295–296

Estrone, bone metabolism role of, in men, 196, 204–208

Ethnicity, as bone strength factor, 31
as fracture risk factor, 168–170
as obesity determinant, 751–753
adolescent prevalence of, 745, 748–751
adult prevalence of, 745–747
children trends prevalence of, 745, 748–750
lipoproteins and, 857–863
type 2 diabetes and, 806
as osteoporosis risk factor, 5–8
biphosphonate indications, 263
genetics of, 74, 76
as peak bone mass factor, 42–44, 50–52

Etidronate, for osteoporosis prevention, guidelines for, 256, 258–259
with surgical hypogonadotropism, 332

Euthyroid sick syndrome (ESS), surgery impact on, 513–515
perioperative management of, 515–516

Euvolemia, hypo-osmolality with, 466–470
treatment of, 473–475

Exercise, as peak bone mass factor, 52–54
excessive, as cause of secondary hypogonadism, 597–598
in obesity treatment, **969–982**
action stage, 973
contemplation stage, 972
facilitating adherence to, 977–980
goal-setting for, 979
home-based versus on-site, 997–998
importance of, 958–959, 969, 980
intensity considerations, 975–977
intermittent, 978
lifestyle approaches, 978–979
programmed versus, 997
long- versus short-bout activity, 997
maintenance stage, 973
medical evaluation before, 970–971
methods of delivering behavioral interventions, 979–980, 987
with high levels of activity, 996–998
motivational readiness for, 970, 972, 977–978
pre-exercise evaluation for, 969–973
precontemplation stage, 970
preparation stage, 972
prescription for adults, 973–977
progressive examples of, 975–976
quantity considerations, 973–975
recent recommendations for, 973–974
resistance exercise benefits, 977
self-monitoring of, 979
transition to action stage, 972
with hypertension, 843–844
with type 2 diabetes, 812

Experimental drug therapy, for obesity, 1016–1021

"Experiments of nature," for bone metabolism, in men, 196–208
alpha-estrogen receptor deficiency, 196
animal "knockouts" of genes, 200–203
aromatase deficiency, 196–200
studies in adults, 204–208
in women, 208–212
challenges to, 208–209
studies in adults, 210–212
studies in animals, 209–210

External laryngeal nerve (ELN), injury with thyroidectomy, 488–492
anatomical relationships, 489–490
evaluation of, 491
introduction to, 488–489
prevention of, 489–491

Extracellular fluid (ECF), decreased, hypovolemia with, 465–466
increased, hypervolemia with, 470–472
normal, euvolemia with, 466–470
plasma osmolality role, 463, 465, 474

Extrapontine myelinolysis (PEM), hyponatremia with, 476–477

F

Family history, for obesity assessment, 939

Fat cell, as endocrine organ, 909

Fecundity, age-related decline in, 681–682
definition of, 669
determinants of, 670–672

Female sex hormones, obesity impact on regulation of, 903–905

Femoral neck, bone mineral density of, in osteoporosis definition, 1–2, 4–8
sex and racial differences in, 30–31, 167–168, 211

Fertility, impaired. See *Infertility*.

Fertilization, as fecundity factor, 670–671

Fetal growth, as growth hormone dependent, 578
maternal diabetes and, 581

Fetal macrosomia, with maternal acromegaly, 578
octreotide impact on, 579

Fetal outcomes, with Cushing's syndrome, 345–347
with pheochromocytoma, 349–350

Fetus, cardiac activity of, in older pregnant women, ultrasonography of, 675–676
maternal adrenal disorders impact on, 578–579, 582–584
maternal aging impact on, 675–676, 682
maternal diabetes impact on, 580–581
maternal thyroid disorders impact on, 575–576

Fine needle aspiration (FNA), of thyroid nodules, during pregnancy, 338–339

Flavonoids. See *Isoflavones*.

Flaxseed, as phytoestrogen source, 235, 249

Flexibility, as bone load capacity factor, 26–28

Fluid regulation. See *Water metabolism*.

Fluid restriction, for hyponatremia, 477–478

Fluoride, for osteoporosis, as anabolic therapy, 286–287
glucocorticoid-induced, 147

FMR1 gene, in human infertility, 558

Focused history, for obesity assessment, 918–920

Folate deficiency, following bariatric surgery, 454–455

Follicle-stimulating hormone (FSH), bone metabolism role of, in men, 196–197, 200
in impaired fertility, 46, XX spontaneous premature ovarian failure, 616, 620–621, 631
aging-related, 672–673, 678, 680
diabetes mellitus and, 580
hypogonadal, 549, 553
autosomal disorders of, 561
in men, 690–691, 693–696, 701
in secondary hypogonadism, 594–595
diagnostic criteria for, 605–606
thyroid disorders and, 574, 577
with polycystic ovary syndrome, 640–641
recombinant versus urinary, 646–647
treatment response, 643–646
perioperative evaluation of, with pituitary tumor, 356, 358

Follicles, ovarian, activation of, 614–615
arrest of growth, in polycystic ovary syndrome, 641–642
as fecundity factor, 671–672
age-related decline in, 672–674
assessment of aging, 678–680
atresia of, 614, 620, 671
depletion of, in age-related infertility, 673, 681
in 46, XX spontaneous premature ovarian failure, 620–623
versus 46, XX spontaneous premature ovarian failure, 615–616, 621, 624
endowment of, 614
expenditure of, 614
function of, 614–615
graafian, in 46, XX spontaneous premature ovarian failure, 617–618, 621

Follicular dysfunction, in 46, XX spontaneous premature ovarian failure, **613–637**
autoimmune oophoritis, 617–620, 628, 631
clinical presentation, 615
counseling for, 627–629
CYP17 mutations, 625
CYP19 mutations, 626
FOXL2 mutations, 624–625
FSHR mutations, 621, 623–624
future strategies for, 631
GALT mutations, 624
genetics of, 555, 559, 562, 564, 621, 623–626
GNAS mutations, 625

Follicular *(continued)*
hormone replacement therapy for, 629–631
idiopathic, 621, 623–626
incidence of, 613
infertility pathophysiology with, 615–617
LHCGR mutations, 624
management of, 627–630
mechanisms of, 617–626
ovarian follicle anatomy and physiology, 614–615
pathogenesis of, 613–614, 631–632
patient evaluation for, 626–627
prognosis of, 630–631
reduced follicle number, 620–623

Folliculogenesis, diabetes mellitus impact on, 580–581

Food and Drug Administration (FDA), approved drugs for obesity, 959–960, 1009–1016
on anti-resorptive agent surrogate markers, for postmenopausal osteoporosis, 171–176

Force, aging bones capacity for, 25–26

46, XX Spontaneous premature ovarian failure, **613–637**
clinical presentation, 615
counseling for, 627–629
future strategies for, 631
genetics of, 555, 559, 562, 564, 621, 623–626
hormone replacement therapy for, 629–631
incidence of, 613
infertility pathophysiology with, 615–617
management of, 627–630
ovarian follicle anatomy and physiology, 614–615
ovarian follicular dysfunction mechanisms, 617–626
autoimmune oophoritis, 617–620, 627, 631
CYP17 mutations, 625
CYP19 mutations, 626
FOXL2 mutations, 624–625
FSHR mutations, 621, 623–624
GALT mutations, 624
GNAS mutations, 625
idiopathic, 621, 623–626
LHCGR mutations, 624
reduced follicle number, 620–623
pathogenesis of, 613–614, 631–632
patient evaluation for, 626–627
prognosis of, 630–631

FOXL2 gene mutations, in 46, XX spontaneous premature ovarian failure, 624–625

Fracture(s), fragility, biomechanical basis of, 25–26, 36–37
in aging bones, 31–36
osteoporosis risks for, 15, 18
biochemical bone markers of, 97–99, 104
biphosphonates impact on, 255–257
bone densitometry prediction of, 166–170
calcitonin impact on, injectable, 274
nasal spray, 275–278
glucocorticoid-induced, 137–138
selective estrogen receptors modulators impact on, 223–226
worldwide epidemiology of, 1–10

Fragile X syndrome, as obesity risk, 825
genetics of, 555, 558
testing indications for, 627

Frasier syndrome, genetics of, 555, 564

Free fatty acids, as hypertension factor with obesity, 832

FSHB gene, in hypogonadal infertility, 553

FSHR gene, in human infertility, 561, 621

FSHR gene mutations, in 46, XX spontaneous premature ovarian failure, 621, 623–624

Functional analysis, in behavioral treatment of obesity, 984–985

Functional loading, adaptation to, osteoporosis and, 21

Funding sources, for weight management programs, 960–961

G

Gabapentin (Neurontin), for surgical hypogonadotropism management, 330–331

Galactosyl hydroxylysine (GHL), as biochemical bone marker, 86–87

Gallbladder disease, as obesity risk, 788, 793–794, 796–797, 929
bariatric surgery and, 441, 443, 450–452

GALT gene mutations, in 46, XX spontaneous premature ovarian failure, 624

Gametes, aging, 671–675
as decline in quantity, quality, or both, 671–674
possible detrimental mechanisms of, 674–675
as fecundity factor, 670–671
obstruction of, genetics of, 550, 565–566

Gastrectomy, secondary osteoporosis following, 123–124

Gastric banding (BG), as bariatric surgery, 444–446

Gastric bypass procedures, in bariatric surgery, 444–445, 454

Gastric restriction procedures, in bariatric surgery, 444–446

Gastrointestinal disease, secondary osteoporosis from, 116, 122–125

Gastrointestinal system, biphosphonates impact on, 260–261
hypothyroidism impact on, 516–517
metabolism of phytoestrogens, 240

Gaucher disease, secondary osteoporosis from, 129

Gender, as bone strength factor, 29–31
during aging, 31–36
as fracture risk factor, 167–169
as obesity determinant, 751–753
adolescent prevalence of, 745, 748–751
adult prevalence of, 745–747
children trends prevalence of, 745, 748–750
lipoproteins and, 857–863
as osteoporosis risk factor, 4–5
as peak bone mass factor, 42–43, 45–48, 55
bone metabolism based on, clinical summary of, 195–196, 213
in men, 196–208
in women, 208–212
non-specificity of, 212–213
cortical bone differences based on, 167–168

Gene mutations. See *Genetics and genetic mutations*.

Genetic risks, with assisted reproductive technology, 556, 567
in age-related infertility, 673–676, 679
in male factor infertility, 691, 693–695
preimplantation genetic diagnosis for, in men, 691
in women, 675–676, 681–682

Genetics and genetic mutations. See also *specific gene*.
as peak bone mass factor, 46, 49–50
of bone formation regulation, 19–20
of bone metabolism, in men, animal "knockout" models of, 200–203
of bone strength, 29–31
of human infertility, **549–572**
chromosomal abnormalities, 555–565
compartment I (hypothalamus), 549–552
compartment II (pituitary), 549, 552–554
compartment III (gonad), 549, 554–555
compartment IV (outflow tract), 550, 565–567
in 46, XX spontaneous premature ovarian failure, 555, 559, 562, 564, 621, 623–626
locational classification of, 549–550
male factors, 559–561, 693–695, 697–699, 702
of obesity, **761–786**
candidate genes approach to, 775–778
genome-wide scans for, 764–775
hypertension and, 843, 882–883
obstructive sleep apnea and, 882–883
overview of, 761–762, 778
singe gene mutations in, 762–764
sydromes associated with, 909
of osteoporosis, **65–81**
approaches to gene identification, 66–69
association studies of candidate genes, 72–77
bone formation and, 19–20, 46, 49–50, 65–66
clinical practice implications, 77
quantitative trait loci for bone mass regulation, in humans, 69–71
in mice, 71
secondary, 116, 120, 127–128
single-gene disorders, 66
bone mass abnormalities and, 69

Genistein, as phytoestrogen source, 234
bone markers and, 239–240, 245
bone mineral density and, clinical trials on, 247–248
mechanism of action, 235–236

Geriatric population, osteoporosis risks in, 8–10, 343
biphosphonates for, 262–263

Germ cells, as fecundity factor, 671
deficiency of, in 46, XX spontaneous premature ovarian failure, 620–621

Germinal vesicle transfer, for aging-related infertility, 681

GIK (glucose-insulin-potassium) infusion, for perioperative management, of diabetes mellitus type 1, 416–417, 420–421, 424

Glargine, for postoperative management, of diabetes mellitus type 1, 425

Glucocorticoid deficiency, hypo-osmolality versus, 469–470

Glucocorticoid-induced osteoporosis (GIOP), **135–157**
calcitonin for, 143–144, 278–279
calcium and vitamin D for, 141–143
diagnostic evaluation of, 140–141
dose correlations, 137–139
epidemiology of, 135–139
in high-risk users, 148–149
parathyroid hormone for, 297
pathogenesis of, 139–140
prevention of, 141–148
secondary, 122
thiazide diuretics for, 143
treatment of, agents for, 141–148
patterns and recommendations for, 147–149
with rheumatic diseases, 129

Glucocorticoid replacement therapy, perioperative management of, **367–383**
adrenal insufficiency caused by, HPA suppression considerations, 371–381
incidence of, 369–370
pitfalls in study of, 370–371
recognition of, 368–369
during pregnancy, 343–347
evolution of, 367–368, 380–381
for thyrotoxicosis, 532–533
HPA suppression with, alternate day therapy and, 376
exogenous ACTH and, 375–376
management of, 375
time course of, 371–372
time course of recovery from, 373–374
hypotension pathogenesis in, 369–370
patient indications for, 377–379
preoperative assessment of adrenocortical function for, 376–377
specific recommendations for, 379–380
with diabetes mellitus type 1, 432–433
with pituitary surgery, 359–360, 364–365

Glucose dosing, perioperative algorithms for, with diabetes mellitus type 1, 418–424

Glucose intolerance, in type 2 diabetes, obesity association with, 788, 793–796, 806, 815, 825, 865
prevention of, 816–818, 932

Glucose monitoring, perioperative, with diabetes mellitus type 1, 421

Glycemic control, for diabetes during pregnancy, 581
with diabetes mellitus type 1, during special surgical scenarios, 428–433
perioperative, 432–433
preoperative transition to in-patient status, 416–417, 419
with diabetes mellitus type 2, obesity association with, 788, 793–796, 806, 815, 825, 865
prevention of, 816–818, 932

GNAS gene mutations, in 46, XX spontaneous premature ovarian failure, 625

GNRHR gene, in hypogonadal infertility, 552–553

Goal-orientation, of behavioral treatment of obesity, 985

Goiter, substernal, in thyroidectomy, for thyroid carcinoma, 500–502

Gonadal dysgenesis, mixed, in male factor infertility, 556, 698

Gonadal failure, in hypogonadal infertility. See *Hypogonadotropic hypogonadism.*

Gonadal steroid replacement therapy. See *Sex hormone replacement therapy.*

Gonadotoxins, in male factor infertility, 699–701

Gonadotropin genes, in hypogonadal infertility, 553–555

Gonadotropin-releasing hormone (GnRH), agonists, for aging-related infertility, 681
deficient secretion in infertility, Cushing's syndrome and, 584
hypogonadal, 550
with diabetes mellitus, 580
gonadal function dependence on, 594
in male factor infertility, 693–696
in secondary hypogonadism, as pulsatile therapy, 606–607
diagnostic tests, 606
pathogenesis, 594–595, 598, 600–602
long-acting analogs of, for polycystic ovary syndrome, 647

Gonadotropin-releasing hormone agonist stimulation test (GAST), for ovarian reserve assessment, 679–680
for secondary hypogonadism diagnosis, 606

Gonadotropins. See also *specific hormone*.
as peak bone mass factor, 42–48, 55
bone metabolism role of, in men, 196, 204–208
for polycystic ovary syndrome with anovulatory infertility, 643–644
follicle-stimulating hormone versus human menopausal, 646
gonadotropin-releasing hormone analogs with low-dose gonadotropins, 647
low-dose regimen, 644
predictors of outcome with, 646
pregnancy outcomes with, 645–646
recombinant human follicle-stimulating hormone, 646–647
results of, 644–645
in 46, XX spontaneous premature ovarian failure, 615–617, 620–621, 623, 625
secondary osteoporosis and, 115, 127

Graafian follicles, in 46, XX spontaneous premature ovarian failure, 617–618, 621

Granulocyte macrophage colony-stimulating factor (GM-CSF), in bone resorption regulation, 18

Grave's disease, perioperative management of, 521–534
evolution of, 521–522, 532–534
postoperative management, 532
preoperative treatment of, 522
preparation for nonthyroid surgery, 531
rapid preparation for surgery, 531–533
surgery indications, 522
surgery risks with, 528–531
therapy goals for, 531, 534

Growth factors. See *Growth hormone (GH)*.

Growth hormone (GH), as peak bone mass factor, 55
deficiency of, associated with obesity, 907
for osteoporosis, 287–288
glucocorticoid-induced, 147
in critically ill patients, 386–393
alterations within acute phase, 386–387
alterations within chronic phase, 387–388
as adverse outcome predictor, 402–403
pathophysiology of chronic changes, 388–390
releasing factors in chronic phase, 390–391
treatment with, 391–393
in human infertility, aging and, 678
hypogonadal, 552, 554
impaired, 578–579
obesity impact on regulation of, 899–901
pituitary surgery and, during pregnancy, 342
perioperative evaluation of, 356–358
replacement therapy for, 359, 361, 363–365

Growth hormone-releasing hormone (GHRH), in critically ill patients, 386–393
alterations within acute phase, 386–387
alterations within chronic phase, 387–388
as chronic phase factor, 390–391
pathophysiology of chronic changes, 388–390
treatment with growth hormone, 391–393
obesity impact on regulation of, 899–900

Growth stages, developmental, of bone strength, 27–28, 31–36

H

Head trauma, as cause of secondary hypogonadism, 604

Health care costs, of weight management programs, 960–961
related to obesity, 787–789

Heart disease, as obesity risk, 788, 791, 793–794, 798–800
hypertension and, 840–842
obstructive sleep apnea and, 878–879

Heart failure, obstructive sleep apnea association with, 107, 877, 929

Heart function, hypothyroidism impact on, 505–509, 516
thyrotoxicosis impact on, 529–530

Hematologic disorders, secondary osteoporosis from, 116–117

Hematoma(s), following thyroidectomy, for thyroid carcinoma, 487–488

Hemochromatosis, secondary osteoporosis from, 121–122

Hemodynamics, hypothyroidism impact on, 505–509, 516

Hemopoietic systems, hypothyroidism impact on, 512–514

Heparin, secondary osteoporosis from, 131

Hepatic disease, secondary osteoporosis from, 124–125

Hepatomegaly, associated with obesity, 929–930

Herbal preparations, binding affinity to estrogen receptors, 236

Herbs, for surgical hypogonadotropism management, 328

HESX1 gene, in hypogonadal infertility, 554

High-density lipoprotein (HDL), in risks with obesity, 791, 793, 799
pathophysiology of, 866–867
type 2 diabetes and, 810–811
relationship to body weight, 857–863

High-protein, low-carbohydrate diet, in behavioral treatment of obesity, 991

Hirsutism, with polycystic ovary syndrome, 639–640

HMG coenzyme A reductase inhibitors, as anabolic therapy, for osteoporosis, 290–291

Homocystinuria, secondary osteoporosis from, 116, 128

Homoeobox genes, in hypogonadal infertility, 554–555

Hormonal mediators, of hypertension with obesity, 828–835, 841

Hormonal status, See also *specific hormone*, as peak bone mass factor, 55, 115, 203

Hormone replacement therapy (HRT), See also *specific hormone*,
for endometriosis-associated infertility, 661
for 46, XX spontaneous premature ovarian failure, 628–631
with pituitary surgery, 359, 364–365

Hospitalized patients, hypo-osmolality in, **461–483**
assessment of, 472
cirrhosis versus, 471–472
congestive heart failure versus, 471
differential diagnosis of, 465–472
glucocorticoid deficiency versus, 469–470
hypothyroidism versus, 470
incidence of, 462
normal plasma osmolality, 461–462
pathogenesis of, 463–465
psychiatric, 470
SIADH versus, 466–469
treatment of, 473–479
acute symptomatic, 475
algorithm for, 473–475
chronic asymptomatic, 476–477
chronic symptomatic, 475–476
fluid restriction for, 477–478
pharmacologic therapy for, 478–479
true versus pseudohyponatremia, 462
with decreased extracellular fluid volume, 465–466
with increased extracellular fluid volume, 470–471
with normal extracellular fluid volume, 466–470

Hot flashes, with surgical hypogonadotropism, management without sex hormone replacement therapy, 326–331

Hot tubs, as male infertility factor, 700

HSD17B3 gene, in human infertility, 562–563

Human chorionic gonadotropin (hCG), for polycystic ovary syndrome, 644
in hypogonadal infertility, 553, 562

Human menopausal gonadotropin (hPG), for polycystic ovary syndrome, 644, 646

Human pituitary gonadotropin (HPG), for polycystic ovary syndrome, 643–644

Hydrocortisone, for pituitary surgery, perioperative stress doses of, 356–357, 359–360
postoperative dosing of, 360–361

Hydroxylase deficiency(ies), impaired fertility with, 581–582, 625, 695

Hydroxyproline (Hyp), as biochemical bone marker, 86–88

Hyperaldosteronism, surgery for primary, during pregnancy, 347–348

Hyperandrogenism, in female athletes, 597–598, 601
in polycystic ovary syndrome, 641–642

Hypercoagulation, obstructive sleep apnea relationship with, 879, 881–882
with hypertension and obesity, 842

Hypercortisolism, in critically ill patients, 371, 400–401

Hyperglycemia, perioperative management of diabetic, detrimental effects of, 414–416
management of, 432–433

Hypergonadotropic hypogonadism, genetics of, 559, 626
secondary hypogonadism versus, 593

Hyperinsulinemia, in polycystic ovary syndrome, 641–642

Hyperlipidemia. See *Dyslipidemia*.

Hyperparathyroidism, secondary osteoporosis from, 122, 126

Hyperprolactinemia, in male factor infertility, 696
secondary osteoporosis from, 119

Hypertension, obesity and, **823–855**
behavioral modification for, 844
biochemical mediators of, 828–835
cardiovascular system changes with, 839–841
cortisol as factor, 831–832
definitions for, 824–825
diagnosis of, 929
epidemiology of, 823–824
free fatty acids factor, 832
genetics of, 843, 882–883
hormonal mediators of, 828–835, 841
insulin as factor, 830–831
leptin as factor, 832–835
mediation of, 835–836
management of, 843–846, 931
natriuretic peptide system role, 838–839
neurochemical mediators of, 828, 835–836
obstructive sleep apnea
association with, pulmonary, 877, 879
systemic, 876–877, 879
pharmacotherapy for, 844–846
physical exercise for, 843–844
proinflammatory changes with, 841–842
prothrombotic changes with, 841–842
renal function alterations in, 826–828
hemodynamic changes, 826–827
structural changes, 827–828
sympathetic nervous system role, 828–830
renin-angiotension aldosterone system role, 836–838
in adipose tissue, 838
systemic, 836–838
risks of, 788, 793, 798
surgery options for, 846
sympathetic nervous system role in, 828–830
thrifty gene hypothesis of, 842–843

Hyperthyroidism, drug therapy for, during pregnancy, 575
hypervascularity and friability with, 529–531
impaired fertility with, 574–575
perioperative management of, 521–534. See also *Thyrotoxicosis*.

Hypervolemia, hypo-osmolality with, 470–472
treatment of, 473–475

Hypo-osmolality, in hospitalized patients, **461–483**
assessment of, 472
cirrhosis versus, 471–472
congestive heart failure versus, 471
differential diagnosis of, 465–472
glucocorticoid deficiency versus, 469–470

Hypo-osmolality *(continued)*
hypothyroidism versus, 470
incidence of, 462
normal plasma osmolality, 461–462
pathogenesis of, 463–465
psychiatric, 470
SIADH versus, 466–469
treatment of, 473–479
acute symptomatic, 475
algorithm for, 473–475
chronic asymptomatic, 476–477
chronic symptomatic, 475–476
fluid restriction for, 477–478
pharmacologic therapy for, 478–479
true versus pseudohyponatremia, 462
with decreased extracellular fluid volume, 465–466
with increased extracellular fluid volume, 470–471
with normal extracellular fluid volume, 466–470

Hypocalcemia, postoperative, 496–498
anatomical relationships, 496–497
introduction to, 496
management of, 498
prevention of, 497–498

Hypogonadism, associated with obesity, 905, 908
causes of, 594
definition of, 549
incidence of, 593
primary. See *Hypergonadotropic hypogonadism.*
secondary. See *Hypogonadotropic hypogonadism.*
secondary osteoporosis from, 115–116, 118–120

Hypogonadotropic hypogonadism, central
causes of, **593–612**
alcohol as, 599–600
anorexia nervosa, 598–599
anticancer treatments as, 601–602
Bardet-Biedl syndrome, 602–603
diagnosis of, 605–606
excessive exercise, 597–598
functional, 595–601
head trauma, 604
hypothalamic amenorrhea, 595–597
hypothalamic-pituitary-gonadal axis in, 594–605
idiopathic, 604, 694–695
infiltrative disease, 604
Kallmann's syndrome, 604–605
Laurence-Moon syndrome, 602–603
miscellaneous drugs as, 601
opioids as, 600–601
oral contraceptives as, 599
organic, 601–605
postpill amenorrhea, 599
Prader-Willi syndrome, 603
psychogenic amenorrhea, 599
smoking as, 600
systemic illness as, critical and chronic, 599
tumors as, 602–603
diagnosis of, in children, 605–606
in women, 605
genetics of, 549–550, 554–555
based on dysfunction location, 550–555
chromosomal abnormalities, 554–565
incidence of, 593
primary hypogonadism versus, 593
treatment of, 606–637

Hypogonadotropism, in critically ill patients, 398–399
surgical management without sex hormone replacement therapy, **325–336**
hormone deficiency overview, 325–326
lifestyle changes for, 326–327, 331
local agents for, 333–334
osteoporosis prevention and treatment, 331–333
pharmaceuticals for, herbal and botanical, 328
traditional non-hormone, 327–328, 332–333
promising unproven approaches to, 330–331
soy products for, 328–330, 333
urogenital symptoms treatment, 333–334
vasomotor symptoms treatment, 326–331

Hyponatremia, 461–462
acute symptomatic, 475
central nervous system role in, 470, 474–477
chronic asymptomatic, 476–477
chronic symptomatic, 475–476
euvolemic, 466–470
fluid restriction for, 477–478
following pituitary surgery, 360, 364–365

hypervolemic, 470–472
hypovolemic, 465–466
in psychiatric patients, 470
initial evaluation of, 472
pharmacologic therapy for, 478–479
symptoms of, 472
treatment algorithm for, 473–475
true versus pseudo-, 462

Hypoparathyroidism, following thyroidectomy, 496–498
anatomical relationships, 496–497
introduction to, 496
management of, 498
prevention of, 497–498

Hypotension, with adrenal insufficiency, perioperative management of, 369–370

Hypothalamic amenorrhea, secondary hypogonadism and, 595–597

Hypothalamic obesity, traumatic, 908

Hypothalamic-pituitary-adrenal (HPA) axis, in critically ill patients, 371, 400–401
insufficiency of. See *Adrenal insufficiency*.
obesity impact on regulation of, 901–903
perioperative suppression of, alternate day therapy and, 376
evolution of, 367–368, 380–381
exogenous ACTH and, 375–376
from glucocorticoid therapy, 375
hypotension pathogenesis in, 369–370
patient indications for, 377–379
preoperative assessment of adrenocortical function for, 376–377
recognition of adrenal insufficiency, 368–369
specific recommendations for, 379–380
time course of, 371–372
time course of recovery from, 373–374
stress-coping hormones secreted by, 598

Hypothalamo-pituitary-gonadal (HPG) axis, gonadal function dependence on, 594–595
functional disorders of, 595–601
organic disorders of, 601–605
in male factor infertility, 693–697

Hypothalamo-pituitary-ovarian (HPO) axis, in female fertility regulation, 573

Hypothalamus dysfunction, in infertility, endocrine disorders, 573
hypogonadal, 549–552

Hypothesis testing, in clinical trials versus jury trials, 715–716
in infertility intervention trials, 716–718

Hypothyroidism, associated with obesity, 907
hypo-osmolality versus, 470
impaired fertility with, 575–576
perioperative management of, **505–520**
cardiovascular system effects, 505–509
coagulation systems effects, 512–514
digestive system effects, 516–517
euthyroid sick syndrome and, 513–516
hemopoietic systems effects, 512–514
parenteral therapy guidelines for, 517
plasma volume effects, 510–512
pulmonary ventilation effects, 508–511
renal function effects, 510–512
thyroid parameters for, 513–515

Hypovolemia, hypo-osmolality with, 465–466
treatment of, 473–475

I

Ibandronate, for osteoporosis, guidelines for, 259

Idiopathic hypogonadotropic hypogonadism (IHH), genetics of, 550–554, 604, 694–695
pathogenesis of, 604

Idiopathic osteoporosis, in men, calcitonin for, 278
in women, biphosphonates for, 263

Idiopathic ovarian follicular dysfunction, 621, 623–626

Idoxifene, for postmenopausal osteoporosis, 229

Imaging techniques, for endometriosis-associated infertility, 655–656
for male factor infertility, 696
for secondary hypogonadism diagnosis, 605

Immobilization, biphosphonate indications for, 264

Impact loading, bone capacity for, 26–29

Impaired fertility. See *Infertility*.

Impaired glucose tolerance (IGT). See *Glucose intolerance*.

In vitro fertilization (IVF), clinical research designs for, 713–714
for aging-related infertility, 673, 675–676, 679
conventional techniques, 680–681
experimental methods, 681
for endometriosis-associated infertility, 658–659, 661–662
for male factor infertility, 691–693, 699, 701, 703
for polycystic ovary syndrome, 647
genetic risks with, 556, 567
aging-related, 673, 675–676, 679

Independent variables, in infertility intervention trials, 720

Infection(s), following thyroidectomy, for thyroid carcinoma, 486–487
with bariatric surgery, 449–450

Infertility, age-related, **669–688**
assisted reproductive technology for, 673, 675, 680–682
extraneous influences on, 671–672, 676–677
fecundity determinants, 669–672, 681–682
gamete aging in, 671–675, 682
genetic risks with, 673–676, 679
in vitro fertilization for, 673, 675–676, 679
conventional techniques, 680–681
experimental methods, 681
male factors of, 671–674, 682
management of, 680–682
neuroendocrine axis and, 678
pregnancy and, 675–676
prognosticators of, 678–680
research review, 669–670, 682
sexuality and, 677–678
anovulatory in polycystic ovary syndrome, **639–651**
cause of, 641–642
clinical characteristics of, 639
diagnosis of, 640–641
insulin and, 641–642
management of, 642–648
prevalence of, 639–640
basic evaluation of, 549
definition of, 549
endocrine dysfunction causes of, **573–592**
adrenal disorders, 581–584
diabetes, 579–581
growth hormone and acromegaly, 578–579
thyroid disorders, 573–577
endometriosis-associated, **653–667**
assisted reproductive technology for, 661
associated mechanisms of, 657–660
clinical appearance of, 655
definition of, 653
diagnostic modalities of, 655–656
epidemiology of, 653–654
medical treatment of, 661
research summary, 662
surgical treatment of, 660, 662
symptoms and signs of, 654
treatment impact on fertility rates, 660–662
genetic causes of, **549–572**
compartment I (hypothalamus), 549–552
compartment II (pituitary), 549, 552–554
compartment III (gonad), 549, 554–555
chromosomal abnormalities, 555–565
compartment IV (outflow tract), 550, 565–567
locational classification of, 549–550
hypogonadism causes of, in women versus men, 549–550
in hypogonadotropic hypogonadism, **593–612**
alcohol as, 599–600
anorexia nervosa, 598–599
anticancer treatments as, 601–602
Bardet-Biedl syndrome, 602–603
diagnosis of, 605–606
excessive exercise, 597–598
functional, 595–601
genetics of, 549–550
based on dysfunction location, 550–555
chromosomal abnormalities, 555–565
head trauma, 604
hypothalamic amenorrhea, 595–597
hypothalamic-pituitary-gonadal axis in, 594–605
idiopathic, 604, 694–695
incidence of, 593
infiltrative disease, 604
Kallmann's syndrome, 604–605

Laurence-Moon syndrome, 602–603
miscellaneous drugs as, 601
opioids as, 600–601
oral contraceptives as, 599
organic, 601–605
postpill amenorrhea, 599
Prader-Willi syndrome, 603
psychogenic amenorrhea, 599
smoking as, 600
systemic illness as, critical and chronic, 599
treatment of, 606–637
tumors as, 602–603
male factors of, **689–707**
age-related, 671–674, 682
from exposure to gonadotoxins, 699–701
genetics of, 559–561, 693–695, 697–699, 702
laboratory evaluation of, 690–691
normal semen criteria, 558
patient history evaluation for, 689–690
physical examination for, 689–690
with cryptorchidism, 699
with ductal system obstructions, 691, 701–702
with ejaculation disorders, 702–703
with endocrinopathies, 693–697
with varicocele, 691–693

Infertility intervention, evaluation efficacy of, **709–722**. See also *specific intervention*.
Cochran Collaboration listing of, 719
pregnancy after, as coincidence versus consequence, 709–710
research design in, 710–721
as dictating statistical analysis, 715–721
clinical context, 713–716, 719
epidemiologic types of, 712–713
example of noninformative, 710–712
statistical analysis in, dependent versus independent variables, 720
dichotomous versus continuous variables, 720
error types with, 715–718
hypothesis testing, 715–718
nonuniform follow-up impact on, 720–721
null hypothesis for, 716–718
outcome measurements for, 718, 720
P values for, 716–718
principals for, 715–719
research design impact on, 715
sample size determination, 718–719
special features of data, 720–721

Infiltrative disease, as cause of secondary hypogonadism, 604

Inflammation, as reaction to biphosphonates, 262
obesity and, hypertension association with, 841
obstructive sleep apnea relationship with, 879, 881

Inflammatory bowel disease, secondary osteoporosis from, 124

Inhibin B, in gamete attrition, 672–673

Insulin, as hypertension factor with obesity, 830–831
dosing for diabetes mellitus type 1, perioperative algorithms for, 418–424
postoperative nomograms for, 425–427
for type 2 diabetes, with obesity, 814–815

Insulin-dependent diabetes mellitus (IDDM), impaired fertility with, 580–581

Insulin hypoglycemia test (ITT), with pituitary surgery, 360–361, 363

Insulin-like growth factor-1 (IGF-1), as anabolic therapy, for osteoporosis, 287–288, 291
glucocorticoid-induced osteoporosis and, 139
in bone formation regulation, 19, 94, 246
in critically ill patients, 386–392
as adverse outcome predictors, 402–403
obesity impact on regulation of, 900–901
with pituitary tumor, perioperative evaluation of, 357–358
postoperative evaluation of, 363–364

Insulin resistance, as obesity risk, 788, 793–796
disease complications with, 806, 825, 865
obstructive sleep apnea and, 879–880
physiology of, 909
weight loss benefits to, 807–809
in polycystic ovary syndrome, 641–642

Insulin-sensitizing drugs, for polycystic ovary syndrome, 648

Insulinoma, associated with obesity, 908

Insurance reimbursement, for weight management programs, 960–961

Intentional weight loss, in obesity risks, 792–793

Intercourse. See *Coitus*.

Interleukin-1 gene cluster, osteoporosis susceptibility based on, 75–76

Interleukin-6, osteoporosis susceptibility based on, 76, 208

Interleukins (ILs), in bone resorption regulation, 17–18, 208

Intermittent exercise, in obesity treatment, 978

Internet, weight management programs on, 980
long-term results of, 980–981

Intracellular fluid (ICF), plasma osmolality role, 463

Intracytoplasmic sperm injection (ICSI), clinical research designs for, 714, 717
for aging-related infertility, 681
for male factor infertility, 691–693, 699, 701

Intrauterine contraceptive device (IUD), efficacy evaluation of, 712–713, 715

Intrauterine insemination (IUI), for aging-related infertility, 680
for male factor infertility, 692, 703

Iodine, for thyrotoxicosis perioperative management, 523–525, 529–531

Ipriflavone, bone mineral density and, 249–250

Iron deficiency, following bariatric surgery, 454–455

Isoflavones, as phytoestrogen source, 234
bone mineral density and, 241–245
clinical trials on, 246–249
mechanism of action, 235–236
synthetic, effects on bone markers and density, 249–250

J

Jury trials, versus infertility intervention clinical trials, 716–717, 721–722

Juvenile osteoporosis, biphosphonates for, 263

K

KA1 gene, in male factor infertility, 694, 696

KAL genes, in secondary hypogonadism, 605

KAL1 gene, in hypogonadal infertility, 550–551, 605

KAL2 gene, in secondary hypogonadism, 605

Kallmann's syndrome, in male factor infertility, 694, 696
secondary hypogonadism with, 604–605

Kartagener syndrome, genetics of, 555, 565

Kennedy's disease, in male factor infertility, 696

Ketokonazole, as teratogenic, 584

Kidney transplantation, secondary osteoporosis from, 126

Kidneys. See *Renal function*.

KIT gene, in 46, XX spontaneous premature ovarian failure, 621

Klinefelter syndrome, genetics of, 674, 697–698
hypogonadism with, 593
secondary osteoporosis from, 119

Knockout models, genetic, of men's bone metabolism, 200–203

L

Laboratory evaluation, as variable, in bone marker measurements, 91
for obesity, 925, 927–928, 939
for obstructive sleep apnea, 875
of osteoporosis,
glucocorticoid-induced, 141
secondary, 132–133

Lactose intolerance, following bariatric surgery, 451

Lactotropic axis, in critically ill patients, 397–398

Langerhans cell histiocytosis (LCH), secondary hypogonadism with, 604

Laparoscopic bariatric surgery, 445–446

Laparoscopic ovarian diathermy (LOD), for polycystic ovary syndrome, 647

Laparoscopy, for endometriosis-associated infertility, diagnostic, 655–656
therapeutic, 660

Lasofoxifene, for postmenopausal osteoporosis, 230

Laurence-Moon syndrome, secondary hypogonadism with, 602–603

Least significant change, in bone marker measurements, 91, 173, 175

LEP genes, in hypogonadal infertility, 550–552

LEPR genes, in hypogonadal infertility, 550–552

Leptin, as obesity factor, endocrine disorders and mongenic mutations, 908–909
hypertension and, 832–835
genetics of, 763
neurochemical mediation of, 835–836
obstructive sleep apnea and, 879–881
physiology of, 909
therapy for, 1016–1017
in bone formation regulation, 20
in hypogonadal infertility, 551–552, 598

Leptin receptors, in hypogonadal infertility, 551–552, 598
obesity role of, genetics of, 763

Leukemias, secondary osteoporosis from, 129

Levormeloxifene, for postmenopausal osteoporosis, 229–230

Leydig cells, in male factor infertility, 695–696, 698

LHB gene, in hypogonadal infertility, 553

LHCGR gene mutations, in 46, XX spontaneous premature ovarian failure, 624

LHR gene, in human infertility, 561–562

LHX3 gene, in hypogonadal infertility, 554

Lifestyle changes, for surgical hypogonadotropism management, 326–327, 331
in obesity treatment, 931–932
exercise as, 978–979
for obstructive sleep apnea, 883–884

Lifestyle history, as peak bone mass factor, 55–57
for obesity assessment, 920–921

Ligans, as phytoestrogen source, 234–235, 240, 249

Linkage analysis, in human pedigrees, for osteoporosis genes, 66–67

Linkage disequilibrium (LD), of osteoporosis genes, 68

Lipoprotein receptor-related protein-5 (LFP-5), in bone formation regulation, 20

Lipoproteins. See also *Dyslipidemia*.
as obesity risk, 791, 793, 799
pathophysiology of, 863–867
type 2 diabetes and, 808, 810–811
body weight impact on, 857–863
selective estrogen receptors modulators impact on, 226–227

Lithium, for hyponatremia, 478
for thyrotoxicosis perioperative management, 524, 527–528

Liver function, secondary osteoporosis and, 124–125

Liver transplantation, secondary osteoporosis from, 126–127

Load and loading, bone capacity for, aging effects on, 25–26, 32, 35–36
compressive, 30
impact, 26–29
material and structure for functional, 26–28
sex and gender differences in, 29–31, 35–36

Local agents, for surgical hypogonadotropism management, without sex hormone replacement therapy, 333–334

LOD score, osteoporosis susceptibility based on, 67, 69–71

Look AHEAD study, for diabetes prevention, 999

Low carbohydrate diets, for obesity, 954–955

Low-density lipoprotein (LDL), in risks with obesity, 791, 793, 799
pathophysiology of, 866, 956
type 2 diabetes and, 808, 810–811
relationship to body weight, 857–863

Low-fat, low-energy-dense diet, in behavioral treatment of obesity, 998–999

Lubricants, for sexual intercourse, as infertility factor, 669–670
urogenital, for surgical hypogonadotropism management, 333

Lugol's solution, for thyrotoxicosis perioperative management, 524–525

Lumbar spine, bone mineral density of, in osteoporosis definition, 3–5, 7–8

Lungs. See *Pulmonary system.*

Luteinizing hormone (LH), bone metabolism role of, in men, 196–197
in critically ill patients, 398–399
in impaired fertility, 46, XX
spontaneous premature ovarian failure, 616, 620, 623, 631
Cushing's syndrome and, 584
diabetes mellitus and, 580
hypogonadal, 549, 553
autosomal disorders of, 561–562
in men, 690–691, 693–696
secondary hypogonadism, 598–599, 601
diagnostic criteria, 605–606
thyroid disorders and, 574, 576
with polycystic ovary syndrome, 640, 646
perioperative evaluation of, with pituitary tumor, 356–358

Luteinizing hormone-releasing hormone (LHRH), in impaired fertility, diabetes mellitus and, 580
secondary hypogonadism, 594–595

Lymphocytic hypophysitis, pituitary surgery and, during pregnancy, 343–344

Lymphomas, secondary osteoporosis from, 129

M

Ma Huang, in obesity therapy, 1019–1020

Macrophage colony-stimulating factor (M-CSF), in bone resorption regulation, 16–17

Magnesium deficiency, with diabetes mellitus, pregnancy loss and, 581

Magnetic resonance imaging (MRI), as bone measurement technique, 40–41
for endometriosis-associated infertility, 655–656
for male factor infertility, 696
for pituitary surgery evaluation, 355–356, 362
during pregnancy, 339, 341, 343
for secondary hypogonadism diagnosis, 605

Mail contact, for weight management programs, 994

Male factor infertility, **689–707**
age-related, 671–674, 682
from exposure to gonadotoxins, 699–701
genetics of, 559–561, 693–695, 697–699, 702
laboratory evaluation of, 690–691
patient history evaluation for, 689–690
physical examination for, 689–690
semen analysis criteria, 558, 690–691, 701–702
with cryptorchidism, 699
with ductal system obstructions, 691, 701–702
with ejaculation disorders, 702–703
with endocrinopathies, 693–697
with varicocele, 691–693

Male sex hormones, obesity impact on regulation of, 903–905, 908, 931

Malignancy(ies). See also *specific type.*
breast, treatments as cause of secondary hypogonadism, 601–602
of bone marrow, secondary osteoporosis from, 129
of thyroid gland. See *Thyroid carcinoma.*

Marfan syndrome, secondary osteoporosis from, 116, 128

Mastocytosis, systemic, secondary osteoporosis from, 130

Maternal outcomes, with Cushing's syndrome, 345–347
with pheochromocytoma, 348–350

MC4R genes, obesity role of, 763–764

Meal replacements, in treatment of obesity, 958, 990

Measurement variability, of bone marker measurements, 88–91

Mediastinal metastasis, of thyroid carcinoma, thyroidectomy considerations, 500–502

Mediterranean Diet, for obesity, 956–957

Megestrol acetate, for surgical hypogonadotropism management, 327

Melanocortin-4 receptors, as hypertension mediator, with obesity, 835–836

Menopause, as fecundity factor, 673–674, 678–679
osteoporosis after. See *Postmenopausal osteoporosis.*
premature, with 46, XX spontaneous ovarian failure, 613, 615–616, 628

Menorrhagia, with hypothyroidism, 573, 575

Menstrual cycle, as fecundity factor, 670–672
age-related changes in, 672–674, 678–679
pituitary surgery impact on, 359, 361, 364–365

Menstrual irregularities, with 46, XX spontaneous premature ovarian failure, 615, 620, 626–627
with acromegaly, 578
with anticancer therapies, 601–602
with diabetes, 580
with excessive exercise, 597–598
with polycystic ovary syndrome, 639–640, 642
with thyroid disorders, 573–576

Meta-analysis, of anti-resorptive agent surrogate markers, for postmenopausal osteoporosis, 172–173

Metabolic syndrome, as obesity risk, 788, 794–796
assessment of, 928, 931–932
diagnostic criteria for, 824–825
with polycystic ovary syndrome, 641–642

Metabolism, bone, sex steroids role in, 195–196, 213
gender non-specificity of, 212–213
in men, 196–208
in women, 208–212
gastrointestinal, of phytoestrogens, 240
mineral, biphosphonates impact on, 262

Metastasis, mediastinal, of thyroid carcinoma, 500–502

Metformin (Glucophage), for polycystic ovary syndrome, 648
in obesity therapy, 1020
with type 2 diabetes, 814, 817–818, 932

Methimazole (MMI), for thyrotoxicosis perioperative management, 524–526, 530

Methotrexate, secondary osteoporosis from, 131

Metyrapone, as teratogenic, 584

Microsurgical reconstruction, for ejaculatory duct obstructions, 701

Mineral metabolism, biphosphonates impact on, 262

Mixed gonadal dysgenesis, in male factor infertility, 556, 698

Moisturizing agents. See *Lubricants.*

Molecular markers, of bone. See *Biochemical bone markers.*

Monoclonal antibodies, in endometriosis-associated infertility, 656

Monofluorophosphate (MFP), as anabolic therapy, for osteoporosis, 286

Monogenic mutations, associated with obesity, 908–909

Monounsaturated fatty acids (MUFA), in type 2 diabetes diets, 810–811

Morbid obesity, bariatric surgery for, **439–459**
age criteria for, 440–441
comorbidities with, improvements in, 452–455
management preoperatively, 441–442
complications of, 447–455
contraindications for, 441
eating behavior and, 450–451
gallbladder disease and, 451–452
increasing need for, 439–440, 455
laparoscopic, 445–446

Morbid (*continued*)
long-term management of, 448–452
patient education/expectations for, 442, 450
patient selection for, 440–441
postoperative management of, 447–448
preoperative management of, 441–443
prevalence of, 439–440, 455–456
procedures for, 444–446
comparison of, 446–447
concerns with, 447–448
screening evaluation for, 442–443
special facilities for, 443–444
support staff for, 443–444
weight loss with, based on procedure, 444, 446–447
benefits of, 452
patient expectations for, 442, 450
conservative treatment options for, 439–440
definition of, 440

Morphologic markers, of ovarian reserve, 673, 679–680

Motivational readiness, for obesity treatment, assessment of, 927, 929–930
exercise programs, 970, 972, 977–978

Mouse/mice studies, of osteoporosis genes, 68–69, 71

Multidisciplinary team, for bariatric surgery, 443–444

Multiple myeloma, secondary osteoporosis from, 129

Muscular atrophy, spinal and bulbar, in male factor infertility, 696

Myomectomy, for infertility, noninformative research design for, 710–712, 720

N

Nasal CPAP, for obstructive sleep apnea, 884–886

Nasal spray calcitonin. See *Calcitonin*.

National Health and Nutrition Examination Survey (NHANES), on obesity, 744–745
drug studies of, 1007
lipoprotein studies, 857–859
prevalence studies of, 747, 749–751
type 2 diabetes in, 805–806

National Health and Nutrition Examination Survey (NHANES III), Third, on osteoporosis, age-related, 2–5, 344
bone densitometry and, 162, 167–169

National Institutes of Health (NIH), on morbid obesity, 440, 446

National Osteoporosis and Risk Assessment (NORA), clinical utility of, 160–161, 166–167

National Weight Control Registry (NWCR), behavioral treatment members of, 995–996

Natriuretic peptide system role (ANP), as hypertension factor with obesity, 838–839

Nerve injury, with thyroidectomy, 488–496
anatomical relationships, 489–490, 492–493, 496
evaluation of, 491
introduction to, 488–489, 492
management of, 495–496
prevention of, 489–491, 493–495
recurrent laryngeal, 492–496, 499–500
superior laryngeal, 488–492
with completion and reoperation, 499–500

Neurochemical mediators, of hypertension with obesity, 828, 835–836

Neuroendocrine axis, aging and, 678

Neuropeptide Y, as hypertension mediator, with obesity, 835–836

Noninformative research design, for infertility intervention efficacy, 710–712

Nonobstructive azoospermia (NOA), 691

Noradrenergic agents, for obesity, 1016

Norepinephrine, obesity impact on regulation of, 905–906

NR5A1 gene, in human infertility, 555, 564

NROB1 gene, in hypogonadal infertility, 550–551

Null hypothesis testing, in infertility intervention trials, 716–718

Nutrition therapy, enteral, for diabetes mellitus type 1, 429–432

following bariatric surgery,
complications with, 453–455
recommendations for, 450–451
for obesity, 931–932
high-protein, low-carbohydrate, 991
low-fat, low-energy-dense, 998–999
meal replacements in, 958, 990
medical model for, **937–967**
National Weight Control Registry for, 995–996
portion-controlled servings, 990–991
prescription spectrum of care, 943–952
reimbursement for, 960–961
very-low-calorie, 990
with type 2 diabetes, 809–813
for ovarian insufficiency, 626–628
for parenteral, diabetes mellitus type 1, 429–432
for polycystic ovary syndrome, 642–643, 648

Nutritional deficiencies, secondary osteoporosis from, 117–119, 122–123

Nutritional supplements, for osteoporosis, 92, 348–349
phytoestrogens as, 233–234
binding affinity to estrogen receptors, 235–236

O

Obesity, as male infertility factor, 694
assessment of patient with, **917–935**
as screening importance, 917–918
chronologic weight gain history, 919
contributing factors history, 918
effect on general health, 920
focused history for, 918–920
identification guidelines, 918
identifying high-risks, 925, 927–929
laboratory tests for, 925, 927–928, 939
lifestyle history for, 920–921
medication history for, 922
morbidity statistics, 793–794, 917
organ/systems review for, 925–927
physical examination for, 922–926, 940–941
previous weight loss attempts history, 919
psychiatric/psychologic history for, 921–922, 940
readiness to change behavior, 927, 929–930
social history for, 921, 939
weight management program expectations, 920
bariatric surgery for. See *Bariatric surgery*.
behavioral treatment of, **983–1005**
characteristics of, 985–986
cognitive restructuring with, 987–988
components of, 987–988
diet focus, high-protein, low-carbohydrate, 991
low-fat, low-energy-dense, 998–999
meal replacements, 958, 990
portion-controlled servings, 990–991
very-low-calorie, 990
with type 2 diabetes, 809–813
evidence for, 983
exercise and, 979–980, 987
high levels of, 996–998
in toxic environment, 999–1000
long-term results of, 991–995
limitations of, 993–994
telephone and mail contact, 994
with on-site treatment, 992
national control registry for, 995–996
principles of, 983–985
research strategies for, 999–1000
self-monitoring of, 986
short-term results of, 989–991
stimulus control in, 986–987
structure of, 988–989
translational research for, 999
with type 2 diabetes, 812–813
body mass index and, assessment guidelines for, 922–925, 941
calculation of, 742
determinant factors of, 751–753, 1008
distribution trends for adults and children, 750–751
genome scans correlation with, 765–769
hypertension and, 824–825
in obstructive sleep apnea, 872, 874
in prevalence studies, 742–744
risks associated with, 787–799
dyslipidemia and, **857–869**

Obesity (*continued*)
lipoproteins and body weight relationship, 857–863
pathophysiology of, 863–867
risks for, 791, 793, 799
endocrine system and, **897–916**
as risk factor, 788, 800–801
diseases associated with, 907–910
Cushing's syndrome, 903, 907
11 β–dehydrogenase deficiency, 910
genetic sydromes, 909
growth hormone deficiency, 907
hypogonadism, 905, 908
hypothyroidism, 907
insulinoma, 908
monogenic mutations, 908–909
polycystic ovarian syndrome, 908
traumatic hypothalamic obesity, 908
fat cell as organ of, 909
regulation mechanisms, 897–907
of catecholamines, 904–906
of corticotropin-cortisol, 901–903
of growth hormone, 899–901
of parathyroid hormone, 906–907
of prolactin, 898–899
of renin-aldosterone, 906
of sex hormones in men, 903–905
of thyroid hormones, 897–898
epidemiologic trends in, **741–760**
definitions with, for adolescents, 743–744
for adults, 742–743
for children, 743–744
for measurement of, 741–742
environmental determinants, 751–753
host determinants, 751–753
prevalence of, 744–751
adolescent trends, 745, 748–751
adult trends, 745–747
body mass distribution trends, 750–751
children trends, 745, 748–750
preventive efforts based on, 754–755
public health impact issues, 755–756
risk factors of, 753–754
exercise in treatment of, **969–982**
action stage, 973
contemplation stage, 972
facilitating adherence to, 977–980
goal-setting for, 979
home-based versus on-site, 997–998
importance of, 958–959, 969, 980
intensity considerations, 975–977
intermittent, 978
lifestyle approaches, 978–979
programmed versus, 997
long- versus short-bout activity, 997
maintenance stage, 973
medical evaluation before, 970–971
methods of delivering behavioral interventions, 979–980, 987
with high levels of activity, 996–998
motivational readiness for, 970, 972, 977–978
pre-exercise evaluation for, 969–973
precontemplation stage, 970
preparation stage, 972
prescription for adults, 973–977
progressive examples of, 975–976
quantity considerations, 973–975
recent recommendations for, 973–974
resistance exercise benefits, 977
self-monitoring of, 979
transition to action stage, 972
with hypertension, 843–844
with type 2 diabetes, 812
genetics of, **761–786**
candidate genes approach to, 775–778
genome-wide scans for, 764–775
hypertension and, 843, 882–883
overview of, 761–762, 778
singe gene mutations in, 762–764
sydromes associated with, 909
high-risk patient identification, 925, 927–929
hypertension and, **823–855**
behavioral modification for, 844
biochemical mediators of, 828–835
cardiovascular system changes with, 839–841
cortisol as factor, 831–832
definitions for, 824–825
epidemiology of, 823–824

free fatty acids factor, 832
genetics of, 843, 882–883
hormonal mediators of, 828–835, 841
insulin as factor, 830–831
leptin as factor, 832–835
mediation of, 835–836
management of, 843–846
natriuretic peptide system role, 838–839
neurochemical mediators of, 828, 835–836
pharmacotherapy for, 844–846
physical exercise for, 843–844
proinflammatory changes with, 841–842
prothrombotic changes with, 841–842
renal function alterations in, 826–828
hemodynamic changes, 826–827
structural changes, 827–828
sympathetic nervous system role, 828–830
renin-angiotension aldosterone system role, in adipose tissue, 838
systemic, 836–838
risks for, 788, 793, 798
surgery options for, 846
sympathetic nervous system role in, 828–830
thrifty gene hypothesis of, 842–843
medical nutrition therapy for, **937–967**
adjust energy balance to prevent weight regain principle, 959–960
as essential, 937–938, 960, 962
behavioral assessment with, 940
decrease of total energy intake principle, 953–954
energy balance assessments, 941–943
energy imbalance and, 938
four principles of, 953–960
increase physical activity principle, 958–959
maintain balanced deficit diet principle, 954–958
personalized assessment with, 938–939
physical examination with, 940–941
psychologic assessment with, 940
reimbursement for, 960–961
spectrum of care with, 943–952
morbid. See *Morbid obesity*.
NHANES program for, 744–745
drug studies of, 1007
lipoprotein studies, 857–859
prevalence studies of, 747, 749–751
type 2 diabetes in, 805–806
nutrition therapy for, 931–932
high-protein, low-carbohydrate, 991
low-fat, low-energy-dense, 998–999
meal replacements, 958, 990
medical model for, **937–967**
National Weight Control Registry for, 995–996
portion-controlled servings, 990–991
prescription spectrum of care, 943–952
very-low-calorie, 990
with type 2 diabetes, 809–813
obstructive sleep apnea and, **871–896**
diagnosis of, 874–875
disease associations with, 875–878
epidemiology of, 871–872, 887
management of, 883–886
mechanisms of disease states, 878–883
pathophysiology of, 872–874
pathology of, 794
pharmacologic therapy and, **1007–1026**
Food and Drug Administration approved, 1009–1016
meta-analysis of, 1007–1009, 1022
potential future, 1016–1021
risks of, **787–804**
associated with excess body weight, 789–791
associated with regional fat distribution, 791, 862, 874
associated with sedentary lifestyle, 792
associated with weight gain, 791–792
cancer as, 788–789, 800
diabetes mellitus type 2 as, 788, 793–796, 805–806
diseases associated with, 787–788
hypersection from enlarged fat cells, 794–801
increased fat mass, 801–802
endocrine changes as, 788, 800–801
gallbladder disease as, 105, 793–794, 796–797, 838

Obesity (*continued*)
health care costs based on, 787–789
heart disease as, 788, 791, 793–794, 798–800
hyperlipidemia as, 791, 793
hypertension as, 788, 793, 798, **823–855**
insulin resistance as, 788, 793–796, 825, 865
intentional weight loss and, 792–793
metabolic syndrome as, 788, 794–796, 824–825
morbidity associated with, 793–794, 917
osteoarthritis as, 788, 801
psychosocial dysfunction as, 788, 802
public health issues, 755–756
skeletal disorders as, 788, 801
skin disorders as, 788, 801
sleep apnea as, 788, 801–802
years of life lost, 789
treatment options for. See also *specific therapy*,
behavioral, **983–1005**
exercise in, **969–982**
pharmacologic, **1007–1026**
surgical, **439–459**,815–816, 844–846, 885
type 2 diabetes and, **805–822**
assessment for, 938–939
impact on, 806–807
prevention of, 816–818, 983, 999
risk association between, 788, 793–796, 805–806
treatment of, 809–816, 932
bariatric surgery, 815–816
behavioral therapy, 812–813
diet, 809–812
exercise, 812
pharmacotherapy, 813–815
weight loss benefits in, 807–809
with polycystic ovary syndrome, 616, 639–640, 648

"Obesity hypertension," 823

Obstruction(s), as human infertility factor, of gametes, 550, 565–566
of male ductal systems, 691, 701–702

Obstructive sleep apnea (OSA), bariatric surgery and, 442–443
hypothyroidism impact on, 509
obesity and, **871–896**
clinical predictors of, 875
diagnosis of, 874–875, 927–928
disease associations with, 875–878
epidemiology of, 871–872, 887
laboratory assessment of, 875
management of, 106˚930, 883–886
drug therapies, 884
lifestyle changes, 883–884
mechanical approaches, 884–886
surgery indications, 885
mechanisms of disease states, 878–883
pathophysiology of, 872–874
symptoms of, 874–875

Octreotide, for acromegaly during pregnancy, 579

Oligomenorrhea, with diabetes, 580
with polycystic ovary syndrome, 639–640

Oligospermia, genetics of, 549–550, 554, 559
WHO criteria for, 558

Oocytes, anatomy and physiology of, 614–615
as fecundity factor, 670–672
age-related decline in, 671–675
degeneration of, in 46, XX spontaneous premature ovarian failure, 621–623
donation of, for 46, XX spontaneous premature ovarian failure, 627–628
for aging-related infertility, 675, 680–681
for endometriosis-associated infertility, 658–659

Oogenesis, hormonal regulation of, 594–595, 615

Oophoritis, autoimmune lymphocytic, in 46, XX spontaneous premature ovarian failure, 617–620, 627, 631

Opioids, as cause of secondary hypogonadism, 600–601

Oral contraceptives (OC), as cause of secondary hypogonadism, 599
research design for efficacy, 712–713

Orchidectomy, bone metabolism after, 203, 209

Organ transplantation, osteoporosis from, biphosphonates for, 264
secondary, 125–127

Orlistat (Xenical), for obesity, 959–960, 1008–1009, 1013–1016
with type 2 diabetes, 814–815

Osmotic gradients, in sodium homeostasis, 463

Osteoarthritis, as obesity risk, 788, 801

Osteoblasts, glucocorticoid-induced osteoporosis and, 139
in bone resorption regulation, 16–20, 33, 37
phytoestrogens impact on, 236–238
with osteoporosis, anabolic therapy impact on, 285, 290, 300
sex steroids impact on, 212–213

Osteocalcin (OC), as biochemical bone marker, 84–85, 90, 92, 94, 96, 98–100
gender differences in, 206–207

Osteoclasts, calcitonin impact on, 273
in bone resorption regulation, 16–18, 20, 33, 37
biphosphonates impact on, 253–254
phytoestrogens impact on, 237–240
with osteoporosis, anabolic therapy impact on, 285, 290, 300

Osteogenesis imperfecta (OI), secondary osteoporosis from, 66, 116, 127–128

Osteoporosis, after menopause. See *Postmenopausal osteoporosis*.
anabolic therapies in, **285–307**
conceptual basis for, 285, 300
fluoride as, 286–287
growth hormone as, 287–288
insulin-like growth factor as, 287–288
parathyroid hormone as, as combination with alendronate, 297
as combination with estrogen, 295–296
as monotherapy post menopause, 292
concerns about, 299–300
continuous versus intermittent, 291–292
in glucocorticoid-induced osteoporosis, 297
in men, 292–295
withdrawal of, 298
statins as, 290–291
strontium as, 288–290
tibolone as, 291
biochemical bone markers of, 92–105
bone loss prediction with, 94–97
current trials on, 92–93
fracture risk prediction with, 97–99, 104
of bone remodeling, 93–94
therapy and, 99–105
biphosphonates for, **253–271**
combining with other treatments, 264
dosing of, 260
duration of therapy, 265
fracture risk reduction with, 255–257
glucocorticoid-induced, 144–146, 149
in special clinical circumstances, 262–264
mechanism of actions, 253–254
monitoring response to, 265
rationale for, 127, 253–254, 265–266, 290–291, 347
side effects of, 260–261
skeletal effects of, 253–255
specific drugs, 255–260
tolerability of, 260–261
bone densitometry for diagnosis by WHO criteria, 159–166
bone remodeling with, 16–18, 342
anabolic therapy impact on, 285, 300
biochemical markers of, 92–105
glucocorticoid-induced, 139–140
bone turnover in, anabolic therapy impact on, 286–300
biochemical markers of, 92–105
predictions based on, 92–100
pretreatment role of, 100–101
therapeutic monitoring role of, 101–105
monogenic bone disease impact on, 69–70
calcitonin therapy for, early menopausal, 275–277
glucocorticoid-induced, 278–279
in combination therapy, 281
postmenopausal, 273–275, 282
calcium and vitamin D for, **339–352**
as therapeutic support, 345–348
physiology of, 339–342
preventive guidelines, 342–345
sources of, 348–349
definition of, 15, 219
epidemiology worldwide, **1–13**
age factor, 1–4
ethnicity factor, 5–8
future prospects for, 9–10
gender factor, 4–5
other risk factors, 8–9
World Health Organization on, 1, 4–5
fracture risk with, 15, 18
bone mineral density prediction for, 166–170

Osteoporosis (*continued*)
selective estrogen receptors modulators impact on, 223–226
genetic determinants of, **65–81**
approaches to identification of, 66–69
association studies of candidate genes, 72–77
bone formation and, 19–20, 46, 49–50, 65–66
clinical practice implications, 77
quantitative trait loci for bone mass regulation, in humans, 69–71
in mice, 71
single-gene disorders, 66
bone mass abnormalities and, 69
glucocorticoid-induced. See *Glucocorticoid-induced osteoporosis*.
idiopathic, biphosphonates for, 263
calcitonin for, 278
pathogenesis of, **15–24**
adaptation to functional loading in, 21
bone formation regulation and, 16, 18–20
bone resorption regulation and, 16–18
coupling defects in, 20–21
multiple pathways in, 15–17, 21
three major reasons for, 16
primary, 16, 115. See also *Primary osteoporosis*.
secondary, 115. See also *Secondary osteoporosis*.
therapeutic response monitoring for, 170–176
with hypogonadotropism, 331–333
incidence of, 331
lifestyle approaches for prevention of, 331
risk factors for, 331
traditional pharmaceutics for, 332–333
with ovarian insufficiency, 626–628

Osteoporosis-pseudoglioma syndrome (OPS), 66, 69

Osteoprotegerin (OPG), 208, 237

Osterix, in bone formation regulation, 19

Ovarian biopsy, for premature ovarian failure evaluation, 621, 623, 625

Ovarian failure, genetics of, 555–558, 567
spontaneous premature 46, XX, **613–637**
autoimmune oophoritis, 617–620, 627, 631
clinical presentation, 615
counseling for, 627–629
CYP17 mutations, 625
CYP19 mutations, 626
FOXL2 mutations, 624–625
FSHR mutations, 621, 623–624
future strategies for, 631
GALT mutations, 624
genetics of, 555, 559, 562, 564, 623–626
GNAS mutations, 625
hormone replacement therapy for, 629–631
idiopathic, 621, 623–626
incidence of, 613
infertility pathophysiology with, 615–617
LHCGR mutations, 624
management of, 627–630
mechanisms of, 617–626
ovarian follicle anatomy and physiology, 614–615
pathogenesis of, 613–614, 631–632
patient evaluation for, 626–627
prognosis of, 630–631
reduced follicle number, 620–623
with endocrine disorders, 573–585

Ovarian follicle. See *Follicles, ovarian*.

Ovarian function, endogenous, phytoestrogens impact on, 240–241

Ovarian reserve, biochemical markers of, 678
diminished, 678
morphologic markers of, 673, 679–680
provocative tests for assessment of, 679–680

Overweight people. See *Obesity*.

Ovulation induction, for aging-related infertility, 680–682

Oxygen saturation, with obstructive sleep apnea, 875

P

P value (probability value), in infertility intervention trials, 716–718

Pain, calcitonin analgesia for, 279–280

Pamidronate, for osteoporosis, glucocorticoid-induced, 145
guidelines for, 259

Pancreatic insufficiency, secondary osteoporosis from, 124

Parathyroid glands, decreased production of. See *Hypoparathyroidism*.
injury with thyroidectomy, 496–498
anatomical relationships, 496–497
introduction to, 496
management of, 498
prevention of, 497–498

Parathyroid hormone (PTH), as anabolic therapy, for osteoporosis, as combination with alendronate, 264, 297
as combination with estrogen, 295–296
as monotherapy post menopause, 292
calcium intake and, 348
concerns about, 174, 299–300
continuous versus intermittent, 291–292
glucocorticoid-induced, 147–148, 297
in men, 292–295
withdrawal of, 298
for osteoporosis prevention, with surgical hypogonadotropism, 332–333
in bone resorption regulation, 17–18, 242, 342
obesity impact on regulation of, 906–907

Parenteral nutrition, diabetes mellitus type 1 management with, 429–432

Patient education, for bariatric surgery, 442

Patient expectations, for weight management programs, 920
with bariatric surgery, 442, 450

Patient selection, for bariatric surgery, 440–441
screening evaluation for, 442–443

PC1 gene, obesity role of, 763

Peak bone mass (PBM), **39–64**
bone mass accrual and, 41–46
critical years of increments of, 42–44
gender differences with, 42–43, 45–48, 55
importance of, 41–42
tracking of, 45–46
bone measurement techniques for, 39–41
determinants of, 46–57
dietary calcium as, 53–56
ethnicity as, 42–44, 50–52
heredity as, 46, 49–50
hormonal status as, 55, 203
lifestyle as, 55–57
physical activity as, 52–54
indications for study of, 39

Pelvis, as age-related infertility factor, pathologies of, 677, 682
vascular insults and, 677
pain in, with endometriosis-associated infertility, 654

Pentoxifylline, for endometriosis-associated infertility, 661

Peptides, as biochemical markers, of bone remodeling, 83–88

Perceived exertion, ratings of, in exercise for obesity, 977

Percutaneous transluminal coronary angioplasty (PTCA), thyroid hormone management during, 508

Perioperative management, of diabetes mellitus type 1, **411–437**
comorbidity effects on, 413
detrimental effects of hyperglycemia on, 414–416
discharge planning in, 425–427
GIK infusion for, 416–417, 420–421, 424
glucose dosing algorithms, 418–424
glucose monitoring for, 421
in non-cardiac versus cardiac patients, 420, 424
incidence of, 411
insulin dosing algorithms, 418–424
pathophysiology of, 412–413
postoperative care for, 425–427
preoperative evaluation for, 413
preoperative preparation for in-patient status, 416–417, 419
scope of, 411–412, 433
special scenarios with, 428–433
with cardiopulmonary bypass surgery, 418–419, 428–429
with enteral or parenteral nutrition, 429–432
with glucocorticoid management, 432–433
with hyperglycemia management, 432–433
with urgent and emergent surgery, 428
of glucocorticoid therapy, **367–383**

Perioperative (*continued*)
adrenal insufficiency caused by, HPA suppression considerations, 371–381
incidence of, 369–370
pitfalls in study of, 370–371
recognition of, 368–369
during pregnancy, 343–347
evolution of, 367–368, 380–381
HPA suppression with, alternate day therapy and, 376
exogenous ACTH and, 375–376
management of, 375
time course of, 371–372
time course of recovery from, 373–374
hypotension pathogenesis in, 369–370
patient indications for, 377–379
preoperative assessment of adrenocortical function for, 376–377
specific recommendations for, 379–380
of hyperthyroidism, 521–534
of hypothyroidism, **505–520**
cardiovascular system effects, 505–509
coagulation systems effects, 512–514
digestive system effects, 516–517
during pregnancy, 337–339
euthyroid sick syndrome and, 513–516
hemopoietic systems effects, 512–514
parenteral therapy guidelines for, 517
plasma volume effects, 510–512
pulmonary ventilation effects, 508–511
renal function effects, 510–512
thyroid parameters for, 513–515
of pituitary surgery, **355–365**
Cushing's syndrome and, 356–360, 362–363
during pregnancy, 339–344
endocrine testing for, 357–359
general principles of, 356–357
ideal, 355
lesion size and, 356
lesion type and, 356
postoperative perspectives, 360–364
replacement therapies and, 359, 364–365
surgical approach and, 356–357
assessing cure with, 362–364
preparation based on, 359–360
of thyrotoxicosis, **521–536**
evolution of, 521–522, 532–534
glucocorticoids for, 532–533
postoperative management, 532
preoperative treatment of, 522
preparation for nonthyroid surgery, 531
rapid preparation for surgery, 531–533
surgery indications, 522
surgery risks with, 528–531
therapy goals for, 531, 534

Periosteal bone, apposition during aging, 31–32, 36
development of surface strength of, 30–31
formation during aging, 35

Peripheral vascular resistance, hypothyroidism impact on, 506, 509

Peritoneal endometriosis, infertility associated with, 654–655

Peroxisome proliferator activated receptor-γ, coactivator-1 (PGC-1) gene, obesity role of, 777

Peroxisome proliferator activated receptor-γ (PPAR-γ) gene, obesity role of, 776–777

Pesticides, as male infertility factor, 700–701

PGC-1 (peroxisome proliferator activated receptor-γ) gene, obesity role of, 776–777

PGC-1 (peroxisome proliferator activated receptor-γ, coactivator-1) gene, obesity role of, 777

Pharmacologic therapy. See *Drug therapy(ies)*.

Phenotypes, osteoporosis susceptibility based on, 66–77

Phentermine, for obesity, 1016

Pheochromocytoma, during pregnancy, 348–351

Photolysis, as variable, in bone marker measurements, 90

Physical activity. See *Exercise*.

Physical examination, for obesity assessment, 922–926, 940–941

Phytoestrogens, **233–252**
as dietary supplements, 233–234

classification of, 234–235
clinical trials on, bone marker and bone mineral density effects, 246–249
caveats in interpretations of, 241
effects of, on bone markers, 241–245
of synthetic agents, 249–250
on bone mineral density, 241–245
clinical trials on, 246–249
on endogenous ovarian function, 240–241
on osteoblasts, 236–238
on osteoclasts, 237–240
synthetic isoflavones, 249–250
gastrointestinal metabolism of, 240
mechanism of action, 235–236
synthetic agents, 249–250

Pickwickian syndrome, associated with obesity, 928

Pituitary adenomas, as cause of secondary hypogonadism, 603
diagnostic symptoms of, 605–606
in male factor infertility, 696
surgery for. See also *Pituitary surgery*, clinically nonfunctioning, 341–342
during pregnancy, 340–341

Pituitary-adrenal axis, in critically ill patients, 371, 400–401
insufficiency of. See *Adrenal insufficiency*.
perioperative suppression of. See *Hypothalamic-pituitary-adrenal (HPA) axis*.

Pituitary dysfunction, in infertility, endocrine disorders, 573, 578–580
hypogonadal, 549, 552–554, 596

Pituitary stalk transection, as cause of secondary hypogonadism, 602

Pituitary surgery, perioperative management of, **355–365**
Cushing's syndrome and, 356–360, 362–363
during pregnancy, 339–344
endocrine testing for, 357–359
general principles of, 356–357
ideal, 355
lesion size and, 356
lesion type and, 356
postoperative perspectives, 360–364
replacement therapies and, 359, 364–365
surgical approach and, 356–357
assessing cure with, 362–364
preparation based on, 359–360
postoperative management of, complications, 362
hormone deficiency, 360–361, 364–365
remission and, 362–364

Pituitary tumor. See *Pituitary adenomas*.

Plasma osmolality, abnormal. See *Hypo-osmolality*.
direct measurement of, 463
normal regulation of, 461–462

Plasma volume, hypothyroidism impact on, 510–512

Plasmaperfusion, charcoal, for thyrotoxicosis perioperative management, 528

Plasmapheresis, for thyrotoxicosis perioperative management, 528

Polycystic ovary syndrome (PCOS), associated with obesity, 908, 927, 929
treatment of, 930–931
bone metabolism and, 210
in anovulatory infertility, **639–651**
cause of, 641–642
clinical characteristics of, 639
clomiphene for, 643
diagnosis of, 640–641
dietary modifications for, 642–643, 648
gonadotropin therapy for, 643–644
follicle-stimulating hormone versus human menopausal, 646
gonadotropin-releasing hormone analogs with low-dose gonadotropins, 647
low-dose regimen, 644
predictors of outcome with, 646
pregnancy outcomes with, 645–646
recombinant human follicle-stimulating hormone, 646–647
results of, 644–645
in vitro fertilization for, 647
insulin resistance and, 641–642
insulin-sensitizing drugs for, 648
laparoscopic ovarian diathermy for, 647
management of, 642–648
prevalence of, 639–640

Polysomnography, for obstructive sleep apnea, 875–876

Population parameter, in clinical research trials, 717

Portion-controlled servings, in behavioral treatment of obesity, 990–991

Postmenopausal osteoporosis (PMO), anti-resorptive agent surrogate markers for, 171–176
primary, bone remodeling markers and, 32–33, 157
calcitonin for, 273–275, 282
early administration of, 275–277
definition of, 16, 115
parathyroid hormone for prevention of, 292
phytoestrogens impact on, 234
bone mineral density and, 241–245
clinical trials on, 246, 248–249
mechanism of action, 235–236
ovarian function and, 240–241
selective estrogen receptors modulators for, **219–232**
bone mineral density effects, 221–223
bone turnover effects, 102, 220–221
clinical interest in, 219–220
extraskeletal effects, 226–229
fracture risk effects, 223–226
new developments, 229–230

Postpill amenorrhea (PPA), in hypogonadotropic hypogonadism, 599

PPAR-γ (peroxisome proliferator activated receptor-γ) gene, obesity role of, 776–777

Prader-Willi syndrome, secondary hypogonadism with, 603, 694–695

Pre-analytical variability, of bone marker measurements, 88–90

Prednisone, secondary osteoporosis from. See *Glucocorticoid-induced osteoporosis (GIOP)*.

Pregnancy. See also *Fecundity*.
acromegaly and, 578–579
adrenal disorders and, 583
after infertility intervention, as coincidence versus consequence, 709–710
with polycystic ovary syndrome, 645–646
aging and, 675–676, 680–682
bariatric surgery and, 452
diabetes mellitus and, 621
endocrine surgery during, **337–354**
for Cushing's syndrome, 344–347
for pheochromocytoma, 348–351
for pituitary disease, 339–344
for primary hyperaldosteronism, 347–348
for thyroid cancer, 337–339
importance of vigilance, 337, 351
secondary osteoporosis from, 130
thyroid disorders and, 575–576
autoimmune, 576–577

Preimplantation genetic diagnosis (PGD), 675–676, 681–682, 691

Premenopausal women, osteoporosis risks in, biphosphonates for, 263

Prevent Recurrence of Osteoporotic Fracture (PROOF) Study, 276–278, 280

Primary biliary cirrhosis (PBC), secondary osteoporosis from, 125

Primary hyperaldosteronism, surgery for, during pregnancy, 347–348

Primary osteoporosis, postmenopausal, anti-resorptive agent surrogate markers for, 171–176
bone remodeling markers and, 32–33, 157
calcitonin for, 273–275, 282
definition of, 16, 115
parathyroid hormone for prevention of, 292
phytoestrogens impact on, 234
bone mineral density and, 241–245
clinical trials on, 246, 248–249
mechanism of action, 235–236
ovarian function and, 240–241
selective estrogen receptors modulators for, **219–232**
bone mineral density effects, 221–223
bone turnover effects, 102, 220–221
clinical interest in, 219–220
extraskeletal effects, 226–229

fracture risk effects, 223–226
new developments, 229–230

Primordial follicles, activation and function of, 615
as fecundity factor, 671, 680
endowment and expenditure of, 614
in autoimmune oophoritis, 618, 631

Probability distribution, in clinical research trials, 717

Probability value (P value), in infertility intervention trials, 716–718

Process-orientation, of behavioral treatment of obesity, 985

Procollagen propeptides, as biochemical bone markers, 84–85, 87, 90–95, 99–104

Progesterone, as fecundity factor, 670
in 46, XX spontaneous premature ovarian failure, 616–618, 620
pituitary surgery impact on, 359, 361, 364–365

Progestin-withdrawal test, for 46, XX spontaneous premature ovarian failure diagnosis, 626–627

Prolactin, in critically ill patients, 397–398
in hypogonadal infertility, 552, 554
in male factor infertility, 690, 693–694, 696
obesity impact on regulation of, 898–899
pituitary tumor impact on, 356–357, 364

Prolactinomas, pituitary surgery for, clinically nonfunctioning, 341–342
during pregnancy, 340–341

Proliferation disorders, of bone marrow, secondary osteoporosis from, 129

Proopiomelanocortin (POMC), as obesity factor, 763
hypertension mediation role, 835–836

PROP1 gene, in hypogonadal infertility, 553–554

Propranolol, for thyrotoxicosis perioperative management, 522, 530–531

Propylthiouracil (PIU), for thyrotoxicosis perioperative management, 524–526

Prostacyclin production, with adrenal insufficiency, perioperative management of, 369

Protein analytes, serum, in endometriosis-associated infertility, 656

Protein diets, for obesity, 954–955

Protein malnutrition, following bariatric surgery, 454–455

Provocative tests, for ovarian reserve assessment, 679–680

Pseudohyponatremia, 462

Psychiatric history, for obesity assessment, 921–922

Psychiatric patients, hyponatremia in, 470

Psychogenic amenorrhea, in hypogonadotropic hypogonadism, 599

Psychologic evaluation, for bariatric surgery, 448, 450
in obesity assessment, 788, 802, 921–922, 940

Psychosexual factors, of infertility, 582

Psychosocial function, obesity impact on, 788, 802
assessment of, 921–922, 939–940

Psychotropic drugs, hypogonadotropic hypogonadism from, 601
in obesity therapy, 1020–1021

Pubertal development, in male infertility, 554, 561
with 46, XX spontaneous premature ovarian failure, 615, 621, 624

Puberty. See *Adolescence*.

Pulmonary emboli (PE), following bariatric surgery, 448

Pulmonary hypertension, obstructive sleep apnea association with, 877, 879

Pulmonary system, hypothyroidism impact on, 508–511

Pyridinoline (PYD), as biochemical bone marker, 86–88, 95

Q

Quantitative computed tomography (QCT), as bone measurement technique, 40, 50
for osteoporosis, age-related, 2–3
glucocorticoid-induced, 141
with anti-resorptive agent surrogate markers, 173
for peak bone mass, 41, 43, 45–48

Quantitative trait loci (QTL), for bone mass regulation, in humans, 69–71
in mice, 71

R

Race. See *Ethnicity*.

Radical neck dissection, with thyroidectomy, for thyroid carcinoma, 486, 498–500

Radiotherapy, as age-related infertility factor, 677
as cause of secondary hypogonadism, 602
as male infertility factor, 700–701

Raloxifene, for postmenopausal osteoporosis, adverse events from, 229
biphosphonate therapy with, 264
bone mineral density effects, 223
bone turnover effects, 102, 104, 220–221
calcitonin therapy and, 281
calcium and vitamin D intake with, 347–348
clinical interest in, 219–220
extraskeletal effects, 226–229
fracture risk effects, 224–226

Random variable, in clinical research trials, 717

Randomized clinical trials, for infertility intervention, 715, 719

Rat studies, of osteoporosis, with testicular feminization, 209–210

Ratings of perceived exertion (RPE), in exercise for obesity, 977

Reactive oxygen species (ROS), in age-related infertility, 674, 681

Readiness for treatment, of obesity. See *Motivational readiness*.

Receiver operating curves (ROC), in osteoporosis measurement, 166–167

Receptor activator of NFK B ligand (RANKL), in bone resorption regulation, 16–17, 208, 237, 291

Recombinant human PTH (rhPTH), for osteoporosis, calcium intake and, 348

Rectifier K^+ current, in phytoestrogen actions, 237, 239

Rectovaginal examination, for endometriosis-associated infertility, 654

Recurrent laryngeal nerve (RLN), injury with thyroidectomy, 492–496
anatomical relationships, 492–493, 496
introduction to, 492
management of, 495–496
prevention of, 493–495
temporary versus permanent, 492
with reoperation, 499–500

Renal function, alterations with obesity and hypertension, 826–828
hemodynamic changes, 826–827
structural changes, 827–828
sympathetic nervous system role, 828–830
hypothyroidism impact on, 510–512

Renal insufficiency, osteoporosis from, biphosphonate indications for, 263–264
secondary, 126

Renin-angiotension aldosterone system (RAAS), as hyperstension factor with obesity, 826–828
in adipose tissue, 838
systemic, 836–838
obesity impact on regulation of, 906, 931

Research design, in infertility intervention efficacy evaluation, 710–721
as dictating statistical analysis, 715–721
clinical context, 713–716, 719
epidemiologic types of, 712–713
example of noninformative, 710–712

Resistance exercise, in obesity treatment, 977

Respiratory distress syndrome (RDS), hypothyroidism impact on, 510

Respiratory function, hypothyroidism impact on, 508–511

Resting energy expenditure (REE), in obesity assessment, 942–943

Rheumatic disease, secondary osteoporosis from, 117, 128–129

Risedronate, for osteoporosis, bone remodeling effects, 101, 105
glucocorticoid-induced, 145–146
guidelines for, 256, 258

Roux-en-Y gastric bypass (RGB), as bariatric surgery, 444–447
nutritional considerations with, 450, 454–455

S

Salmon calcitonin. See *Calcitonin*.

Sample collection mode, as variable, in bone marker measurements, 90–91

Sample size determination, in infertility intervention trials, 718–719

Sample statistic, in clinical research trials, 717

Sarcoidosis, secondary hypogonadism with, 604

Sclerostin, in bone formation regulation, 20

Screening evaluation, for bariatric surgery, 442–443
  patient selection with, 440–441

Secondary osteoporosis, **115–134**
  causes of, 115–117
  definition of, 115
  diagnostic evaluation for, 132–133
  from bone marrow disorders, 129
  from endocrine disorders, 116, 120–122
  from gastrointestinal disease, 116, 122–125
  from hypogonadism, 115–116, 118–120
  from inherited skeletal disorders, 127–128
  from medications, 117, 130–131
  from organ transplantation, 125–127
  from pregnancy, 130
  from premenopausal estrogen deficiency, 115–116, 118–120
  from rheumatic disease, 117, 128–129
  from systemic mastocytosis, 130
  genetics of, 116, 120, 127–128

Sedentary lifestyle, in risks with obesity, 792

Selection bias, in clinical research trials, 715, 721

Selective estrogen receptors modulators (SERMs), for osteoporosis in men, 208
  for postmenopausal osteoporosis, **219–232**
    bone mineral density effects, 221–223
    bone turnover effects, 102, 220–221
    calcitonin therapy and, 281
    clinical interest in, 219–220
    extraskeletal effects, 226–229
    fracture risk effects, 223–226
    new developments, 229–230

Selective serotonin reuptake inhibitors (SSRIs), for surgical hypogonadotropism management, 327

Self-monitoring, in obesity treatments, behavioral, 986
    with exercise, 979

Semen analysis. See also *Sperm entries*.
  for infertility evaluation, 690–691
    with excretory duct obstructions, 701–702
  normal, WHO criteria for, 558, 691

Sex. See *Gender*.

Sex chromosomes, infertility abnormalities of, age-related aneuploidy, 674, 679–680
    autosomal, 555, 561–565
    in men, 677–679
    Klinefelter's syndrome, 674, 697–698
    of X chromosome, 554–559, 698
    of Y chromosome, 554–555, 559–561, 698–699

Sex-determining (SRY) gene, in human infertility, 554, 559, 698

Sex hormone-binding globulin (SHBG), thyroid disorders and, 574–575

Sex hormone replacement therapy, management of patients unable to take, **325–336**
    hormone deficiency overview, 325–326
    lifestyle changes for, 326–327, 331
    local agents for, 333–334
    osteoporosis prevention and treatment, 331–333
    pharmaceuticals for, herbal and botanical, 328
      traditional non-hormone, 327–328, 332–333
    promising unproven approaches to, 330–331
    soy products for, 328–330, 333
    urogenital symptoms treatment, 333–334
    vasomotor symptoms treatment, 326–331
  with pituitary surgery, 359, 361, 364–365

Sex hormones. See also *specific hormone*.
  bone metabolism role of, 195–196, 213

Sex hormones (*continued*)
gender non-specificity of, 212–213
in men, 196–208
in women, 208–212
obesity impact on regulation of, in men, 903–905, 908
treatment of, 931

Sexuality, aging and, 677–678

Sheehan's syndrome, pituitary surgery and, during pregnancy, 342–343
secondary hypogonadism with, 603

Short ACTH stimulation test, for perioperative glucocorticoid management, in preoperative assessment, 376–377
with diabetes mellitus type 1, 432–433

Sibutramine (Meridia), for obesity, 959, 1008–1013
with type 2 diabetes, 813–814

Single-gene disorders, with osteoporosis, 66
bone mass abnormalities and, 69
linkage analysis in pedigrees, 66–67

Skeletal disorders, as obesity risk, 788, 801
inherited, secondary osteoporosis from, 127–128

Skin disorders, as obesity risk, 788, 801

Sleep apnea, as obesity risk, 788, 801–802
obstructive. See *Obstructive sleep apnea (OSA)*.

Smoking behavior. See *Tobacco use*.

Social history, for obesity assessment, 788, 802, 921, 939

Sodium, serum, decreased. See *Hyponatremia*.
intracellular versus extracellular dynamics of, 463, 465–472, 474
normal regulation of, 461–462

Sodium chloride (NaCl), in hypo-osmolality treatment, 473–477

Somatotropic axis, in critically ill patients, 386–393
alterations within acute phase, 386–387
alterations within chronic phase, 387–388
as adverse outcome predictors, 402–403
cortisol levels and, 371, 400–401
GH-releasing factors in chronic phase, 390–391
pathophysiology of chronic changes, 388–390
treatment with growth hormone, 391–393

SOX9 gene, in human infertility, 564

Soy products, for surgical hypogonadotropism management, 328–330, 333

Soy protein, as phytoestrogen source, 234
bone mineral density and, 241–245
clinical trials on, 246, 248–249
mechanism of action, 235–236
ovarian function and, 240–241

Sperm, absence of. See *Azoospermia*.
as fecundity factor, 671–672
age-related decline in, 672–674, 682

Sperm aspiration, microsurgical epididymal (MESA), for sperm retrieval, 701

Sperm injection, for infertility. See *specific technique*.

Spermatic veins, dilation of, male infertility with, 691–693

Spermatogenesis, evaluation of, for male infertility, 691, 694, 697, 702
genetics of, in human infertility, 559–561

Spinal cord lesions, as male infertility factor, 702

Spironolactone, pregnancy contraindication for, 348

SRD5A2 gene, in human infertility, 562–563

SRY (sex-determining) gene, in human infertility, 554, 559, 698

SSKI, for thyrotoxicosis perioperative management, 524–525

Standard deviation (SD) scores, in various bone measurement devices, for WHO osteoporosis criteria, 159–160, 162–165, 169

StAR gene, in human infertility, 562–563, 695

Statins, as anabolic therapy, for osteoporosis, 290–291

Statistical analysis, in infertility intervention efficacy evaluation, dependent versus independent variables, 720
dichotomous versus continuous variables, 720
error types with, 715–718
hypothesis testing, 715–718
nonuniform follow-up impact on, 720–721
null hypothesis for, 716–718
outcome measurements for, 718, 720
P values for, 716–718
principals for, 715–719
research design impact on, 715
sample size determination, 718–719
special features of data, 720–721

Steatorrhea, following bariatric surgery, 451

Steroid cell autoimmunity, in 46, XX spontaneous premature ovarian failure, 619–620

Steroid enzyme genes, in human infertility, 562–563

Steroidogenesis, drugs inhibiting during pregnancy, 584
gene defect locations in, 562–564
ovarian follicle role in, 615

Steroids, anabolic androgenic, hypogonadotropic hypogonadism from, 601, 696–697
perioperative management of. See *Glucocorticoid replacement therapy*.
secondary osteoporosis from. See *Glucocorticoid-induced osteoporosis (GIOP)*.

Stiffness, as bone load capacity factor, 26–27, 29

Stress risers, in bone remodeling, 254, 257

Strontium, as anabolic therapy, for osteoporosis, 288–290

Structural basis, of bone strength. See *Biomechanical basis;Bone strength*.

Structural failure, of bones. See *Fracture(s)*.

Substernal goiter, in thyroidectomy, for thyroid carcinoma, 500–502

Superior laryngeal nerve, injury with thyroidectomy, for thyroid carcinoma, 488–492

Surgery. See also *Perioperative management*.
diabetes mellitus type 1 management for, **411–437**
for obesity-related diseases, bariatric, **439–459**, 815–816
hypertension, 844–846
obstructive sleep apnea, 885
glucocorticoid management for, **367–383**
hyperthyroidism management for, **521–536**
hypothyroidism management for, **505–520**
pituitary management for, **355–365**
pregnancy and, endocrine concerns with, **337–354**

Surrogate markers, for osteoporosis-specific therapies, 170–176

Swyer syndrome, genetics of, 559

Sympathetic nervous system (SNS), role in obesity-related diseases, endocrine disorders, 904–906
hypertension as, 828–835
obstructive sleep apnea as, 879, 882

Sympathomimetic agents, for male ejaculation disorders, 702

Syndrome of inappropriate diuretic hormone (SIADH), 466–469
arginine vasopressin role in, 467–469
common etiologies of, 468
criteria for diagnosis of, 467
treatment of, 473–475, 477–479

Syndrome X. See *Fragile X syndrome*.

Synthetic isoflavones, effects on bone markers and density, 249–250

Systemic hypertension, obstructive sleep apnea association with, 876–877, 879

Systemic illness(es), critical and chronic, as male infertility factor, 690
secondary hypogonadism with, 599

Systemic mastocytosis, secondary osteoporosis from, 130

Systems review, for obesity assessment, 925–927

T

T cells, in bone resorption regulation, 17–18

T-score Equivalency Project, 164–165

T scores, in various bone measurement devices, for gender-related osteoporosis, 197

T cells (*continued*)
for WHO osteoporosis criteria, 160–165

Tamoxifen, for postmenopausal osteoporosis, adverse events from, 229
bone mineral density effects, 221–223
bone turnover effects, 220
clinical interest in, 219–220
extraskeletal effects, 226–229
fracture risk effects, 223–224

Tartrate-resistant acid phosphatase 5b (TRACP 5b), as biochemical bone marker, 87–88

Telephone prompts, for weight management programs, 979–980, 994

Teratogens, Cushing's syndrome drugs as, 584

Testicular biopsy, for male factor infertility, 691

Testicular feminization, bone metabolism and, 208–210

Testicular sperm extraction (TESE), for male infertility evaluation, 691, 699

Testosterone, bone metabolism role of, gender non-specificity of, 212–213
in men, 196, 204–208
in women, 211
critical illness impact on, 398–399
for osteoporosis, glucocorticoid-induced, 144
in male factor infertility, 693–697
in surgically hypogonadal patients, osteoporosis prevention and treatment, 331–333
overview of, 325–326
urogenital symptoms treatment, 333–334
vasomotor symptom treatment, 326–331
pituitary surgery impact on, 359, 361, 364–365

Therapeutic Lifestyl Changes (TLC) diet, for obesity, 955

Thermodegradation, as variable, in bone marker measurements, 90

Thiazide diuretics, for osteoporosis, glucocorticoid-induced, 143

Thiazolidinediones (TZDs), for polycystic ovary syndrome, 648

Thionamides, for thyrotoxicosis perioperative management, 524–526, 529–530
emergent preparation, 532–533

Thrifty gene hypothesis, of hypertension and obesity, 842–843

Thrombosis, with hypertension and obesity, 842

Thyroid carcinoma, completion thyroidectomy and neck reoperation for, 498–500
factors increasing suspicion for, 339
mediastinal metastasis of, 500–502
thyroidectomy for, **485–504**
during pregnancy, 337–339
hematoma with, 487–488
historical perspectives of, 485–486
hypoparathyroidism following, 496–498
infections with, 486–487
metastasis considerations, 500–502
nerve injury with, 488–496
recurrent laryngeal, 492–496, 499–500
superior laryngeal, 488–492
reoperation circumstances, 498–500
substernal goiter and, 500–502
tracheal edema with, 487
vascular complications of, 487–488
wound healing with, 486–487

Thyroid disorders, impaired fertility with, 573–577
secondary osteoporosis from, 120–121

Thyroid gland, hypervascularity and friability of, with hyperthyroidism, 529–531

Thyroid hormone(s), as peak bone mass factor, 55
decreased. See *Hypothyroidism*.
in critically ill patients, 393–397
changes in acute phase, 393–394
changes in prolonged phase, 394–395
treatment with, 395–397
treatment with releasing factors, 395–397
increased. See *Hyperthyroidism*.
obesity impact on regulation of, 897–898, 907, 928
surgery impact on, 513–515
perioperative management of, 515–517, 531

Thyroid hormone replacement therapy,
parenteral administration guidelines, 517
with pituitary surgery, 359, 364–365

Thyroid nodules, carcinoma incidence with, 337–338

Thyroid releasing hormone (TRH), in
critically ill patients, 393–397
changes in acute phase, 393–394
changes in prolonged phase, 394–395
treatment with, 395–397
treatment with thyroid hormone, 395–397
surgery impact on, 513–515

Thyroid-stimulating hormone (TSH), as
nodule growth factor, 338
disorders with infertility,
hypogonadal, 552–554
in women, 574, 576
in critically ill patients, 393–397
changes in acute phase, 393–394
changes in prolonged phase, 394–395
treatment with releasing factors, 395–397
treatment with thyroid hormone, 395–397
surgery impact on, 513–515, 531
with pituitary tumor, perioperative
evaluation of, 356–357
postoperative deficiency of, 361

Thyroidectomy, for thyroid carcinoma, **485–504**
completion and neck reoperation, 498–500
during pregnancy, 337–339
hematoma with, 487–488
historical perspectives of, 485–486
hypoparathyroidism following, 496–498
infections with, 486–487
mediastinal metastasis and, 500–502
nerve injury with, 488–496
recurrent laryngeal, 492–496, 499–500
superior laryngeal, 488–492
substernal goiter and, 500–502
tracheal edema with, 487
vascular complications of, 487–488
wound healing with, 486–487
for thyrotoxicosis, 522–523

Thyrotoxic patient. See *Thyrotoxicosis*.

Thyrotoxicosis, perioperative management of, **521–536**
β-blockers for, 522–524, 526–527
cardiovascular manifestations of, 529–530
cholecystographic agents for, 524, 527
evolution of, 521–522, 532–534
glucocorticoids for, 532–533
iodine for, 523–525
lithium for, 524, 527–528
pharmacologic therapy for, 524–528
surgical risks with, 529–531
plasma treatments for, 528
postoperative management, 532
preoperative treatment of, 522
preparation for nonthyroid surgery, 531
rapid preparation for surgery, 531–533
surgery indications, 522
surgery risks with, 528–531
therapy goals for, 531, 534
thionamides for, 524–526
thyroidectomy indications for, 522–523

Thyrotropic axis, in critically ill patients, 393–397
as adverse outcome predictors, 402–403
changes in acute phase, 393–394
changes in prolonged phase, 394–395
treatment with releasing factors, 395–397
treatment with thyroid hormone, 395–397

Tibolone, as anabolic therapy, for osteoporosis, 291

Timing, as variable, in bone marker measurements, 90–91

Tissue mineral density, of bone. See *Bone mineral density (BMD)*.

Tobacco use, as age-related infertility factor, 676–677
as cause of secondary hypogonadism, 600
as male infertility factor, 700
as osteoporosis risk factor, 8, 126, 344
as peak bone mass factor, 56
in obesity assessment, 939

Topiramate (Topamax), for obesity, 1018–1019

Total body water, homeostatic regulation of, 461–462
during pregnancy, 344

Total energy expenditure (TEE), in obesity assessment, 942–943

Total energy intake (TEI), as weight loss principle, 953–954

Total parenteral nutrition (TPN), diabetes mellitus type 1 management with, 429–432

Toxic environment, in behavioral treatment of obesity, 999–1000

Trabecular bone, aging remodeling of, 28–29, 32–34

Tracheal edema, following thyroidectomy, for thyroid carcinoma, 487

Transcription factors, in bone formation regulation, 19–20

Transforming growth factor (TGF), in bone resorption regulation, 17, 20

Transforming growth factor beta-1, osteoporosis susceptibility based on, 75

Translocations, autosome, of X-chromosome, 557–558, 698

Transplantations. See *Organ transplantation.*

Traumatic hypothalamic obesity, 908

Treatment delivery modesl, for weight management programs, 960–961

Triglycerides, obesity role of, body weight and metabolism, 857, 859, 935
elevated levels, 865–867

Tumor necrosis factor (TNF), in bone resorption regulation, 17, 237

Tumor necrosis factor receptor 2, osteoporosis susceptibility based on, 76–77

Tumors. See also *specific type.*
as cause of secondary hypogonadism, 602–603, 605–606
as male infertility factor, 696

Turner syndrome, genetics of, 555–556, 674
secondary osteoporosis from, 118

Type 1 diabetes. See *Diabetes mellitus type 1.*

Type 2 diabetes. See *Diabetes mellitus type 2.*

U

Ultrasonography, for age-related infertility, 679–680
for endometriosis-associated infertility, 656
for fetal cardiac activity, in older women, 675–676
transrectal (TRUS), for male factor infertility, 701

Ultraviolet radiation, as variable, in bone marker measurements, 90

Undermasculinization, genetics of, 555, 564, 566

Upper airway occlusion, in obstructive sleep apnea, 872–873

Urea, for hyponatremia, 478

Urgent surgery, diabetes mellitus type 1 management during, 428
thyrotoxicosis management during, 531–533

Urine osmolality, hypothyroidism impact on, 510–512
normal regulation of, 461–462

Urogenital symptoms, of surgical hypogonadotropism, management without sex hormone replacement therapy, 333–334

Uterus, aging, declining fertility with, 675
receptivity of, as fecundity factor, 670–671
selective estrogen receptors modulators impact on, 227–228

V

Vaginal lubricants, for sexual intercourse, as infertility factor, 669–670
for surgical hypogonadotropism management, 333

Variability, of bone marker measurements, 88–91

Variables, in infertility intervention trials, dependent versus independent, 720
dichotomous versus continuous, 720
incomplete follow-up as, 720–721
random, 717

Varicocele, male infertility with, 691–692
repair outcomes of, 692–693

Vas deferens, obstruction of, as male infertility factor, 701–702

Vascular adaptation, with hypertension and obesity, 839–840, 842

Vascular endothelial growth factor (VEGF), aging gametes and, 674–675

Vascular insults, pelvic, as age-related infertility factor, 677

Vasomotor symptoms, of surgical hypogonadotropism, management without sex hormone replacement therapy, 326–331

Vasopressin, therapeutic. See *Arginine vasopressin (AVP)*.

Vasopressin receptor antagonists, for hyponatremia, 479

Vein dilation, spermatic, male infertility with, 691–693

Ventilation, hypothyroidism impact on, 508–511

Vertical banded gastroplasty (VBG), as bariatric surgery, 444–446
  nutritional considerations with, 453–454

Very-low-calorie diets (VLCDs), in behavioral treatment of obesity, 944, 990
  guidelines for, 945, 953–954
  with type 2 diabetes, 811–812

Very-low-density lipoprotein (VLDL), in obesity pathophysiology, 861, 865–866

Vibratory stimulation, for male ejaculation disorders, 702

Vitamin(s), deficient absorption of, following bariatric surgery, 454–455

Vitamin B12 deficiency, following bariatric surgery, 454–455

Vitamin D, absorption of, bariatric surgery and, 455
  factors of, 340–342
  deficiency of, bone remodeling and, 92
    secondary osteoporosis from, 117–119, 122–123, 126–127
  for osteoporosis, **339–352**
    glucocorticoid-induced, 141–143
    nasal calcitonin therapy and, 72
    physiology of, 340–342
    preventive guidelines for, 332, 342, 345
    sources of, 349
    supportive guidelines for, 345–348
  intake recommendations for, 92, 342, 349
  normal serum values of, 342

Vitamin D receptor (VDR) genotype, as peak bone mass factor, 46, 49–50
  osteoporosis susceptibility based on, 71–73

Vitamin E, for surgical hypogonadotropism management, 328

Vitamin K deficiency, osteoporotic fracture risks and, 99

Vomiting, following bariatric surgery, 451

von Willebrand's disease, hypothyroidism impact on, 512–513

W

Water metabolism, during pregnancy, 344
  hypothyroidism impact on, 507, 509–512
  normal, 461–462
  pathogenic, 463–465

WATTS protocol, for perioperative management, of diabetes mellitus type 1, 424

Weight gain, in risks with obesity, 791–792, 919

Weight loss, benefits of, in type 2 diabetes, 807–809, 932
  four principles of, 953–960
  spectrum of care with programs for, 943–952
  with bariatric surgery, based on procedure, 444, 446–447
    benefits of, 452
    patient expectations for, 442, 450

Weight management programs. See also *Exercise; Nutrition*.
  expectations of obese patients, 920
  for type 2 diabetes, 809–812, 932
  LEARN, 986, 988
  on Internet, 980
  reimbursement for, 960–961

Wnt signaling, in bone formation regulation, 19–20

Wolff-Chaikov effect, of iodine, for thyrotoxicosis, 525

World Health Organization (WHO),
  normal semen analysis criteria of, 558, 691
  on osteoporosis, diagnostic criteria, 159–166
    epidemiology perspectives, 1, 4–5

Wound healing, following thyroidectomy,
for thyroid carcinoma, 486–487
with bariatric surgery, 448–450

WT1 gene, in human infertility, 564

X

X chromosome, infertility abnormalities of, 554–559
autosome translocations, 557–558, 698
entire deletions, 555–556
partial deletions, 556–557
single-gene, 558

X-linked recessive genes, in hypogonadal infertility, 550–551, 694

Y

Y chromosome, infertility abnormalities of, 554–555, 558–561, 698–699

Years of life lost, with obesity, 789

Z

Zoledronate, for osteoporosis, bone turnover effects, 102–103
guidelines for, 259–260

Zone Diet, for obesity, 954–955

Zonisamide (Zonegran), for obesity, 1018–1019